Published on in Vol 7, No 4 (2021): April

Preprints (earlier versions) of this paper are available at, first published .
Convalescent Plasma for the Prevention and Treatment of COVID-19: A Systematic Review and Quantitative Analysis

Convalescent Plasma for the Prevention and Treatment of COVID-19: A Systematic Review and Quantitative Analysis

Convalescent Plasma for the Prevention and Treatment of COVID-19: A Systematic Review and Quantitative Analysis

Authors of this article:

Henry T Peng1 Author Orcid Image ;   Shawn G Rhind1 Author Orcid Image ;   Andrew Beckett2, 3 Author Orcid Image


1Defence Research and Development Canada, Toronto Research Centre, Toronto, ON, Canada

2St. Michael’s Hospital, Toronto, ON, Canada

3Royal Canadian Medical Services, Ottawa, ON, Canada

Corresponding Author:

Henry T Peng, PhD

Defence Research and Development Canada

Toronto Research Centre

1133 Sheppard Avenue West

Toronto, ON, M3K 2C9


Phone: 1 416 635 2129


Related ArticleThis is a corrected version. See correction statement in:

Background: The COVID-19 pandemic, caused by a novel coronavirus termed SARS-CoV-2, has spread quickly worldwide. Convalescent plasma (CP) obtained from patients following recovery from COVID-19 infection and development of antibodies against the virus is an attractive option for either prophylactic or therapeutic treatment, since antibodies may have direct or indirect antiviral activities and immunotherapy has proven effective in principle and in many clinical reports.

Objective: We seek to characterize the latest advances and evidence in the use of CP for COVID-19 through a systematic review and quantitative analysis, identify knowledge gaps in this setting, and offer recommendations and directives for future research.

Methods: PubMed, Web of Science, and Embase were continuously searched for studies assessing the use of CP for COVID-19, including clinical studies, commentaries, reviews, guidelines or protocols, and in vitro testing of CP antibodies. The screening process and data extraction were performed according to PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) guidelines. Quality appraisal of all clinical studies was conducted using a universal tool independent of study designs. A meta-analysis of case-control and randomized controlled trials (RCTs) was conducted using a random-effects model.

Results: Substantial literature has been published covering various aspects of CP therapy for COVID-19. Of the references included in this review, a total of 243 eligible studies including 64 clinical studies, 79 commentary articles, 46 reviews, 19 guidance and protocols, and 35 in vitro testing of CP antibodies matched the criteria. Positive results have been mostly observed so far when using CP for the treatment of COVID-19. There were remarkable heterogeneities in the CP therapy with respect to patient demographics, donor antibody titers, and time and dose of CP administration. The studies assessing the safety of CP treatment reported low incidence of adverse events. Most clinical studies, in particular case reports and case series, had poor quality. Only 1 RCT was of high quality. Randomized and nonrandomized data were found in 2 and 11 studies, respectively, and were included for meta-analysis, suggesting that CP could reduce mortality and increase viral clearance. Despite promising pilot studies, the benefits of CP treatment can only be clearly established through carefully designed RCTs.

Conclusions: There is developing support for CP therapy, particularly for patients who are critically ill or mechanically ventilated and resistant to antivirals and supportive care. These studies provide important lessons that should inform the planning of well-designed RCTs to generate more robust knowledge for the efficacy of CP in patients with COVID-19. Future research is necessary to fill the knowledge gap regarding prevention and treatment for patients with COVID-19 with CP while other therapeutics are being developed.

JMIR Public Health Surveill 2021;7(4):e25500



SARS-CoV-2, the cause of COVID-19, was declared a pandemic in early 2020 by the World Health Organization [1,2]. This is the third coronavirus to emerge in the past two decades, causing multinational outbreaks and carrying substantial morbidity and mortality [3]. COVID-19 is characterized by a spectrum of symptoms, ranging from mild subclinical infection with self-limiting respiratory tract illness (dry cough, fever, fatigue, difficulty breathing) to severe progressive manifestations (acute respiratory distress, hypercoagulation, hyperinflammation, multi-organ dysfunction, death) in high-risk patients with known comorbidities (advanced age, diabetes, obesity, cardiopulmonary disease) [4,5]. Case-fatality rates range from 4% to 50%, with higher mortality observed in the most critically ill [6]. Growing evidence also suggests that some patients with COVID-19, including those with milder symptoms, will have a prolonged course of recovery including fatigue, cognitive impairment, and cardiopulmonary dysfunction [7]. As such, COVID-19 represents an overwhelming universal health crisis [8], and the burden of this disease continues to threaten lives and livelihoods worldwide [9]. As SARS-CoV-2 and its emerging new mutant strains (which may be associated with an increased efficiency of viral replication, transmission, and virulence in humans) continue to spread globally, international research efforts are being accelerated to identify effective preventive and therapeutic approaches to mitigate its impact [10-12].

The magnitude and urgency of this public health emergency has prompted global scientific collaborations to seek rapid solutions via repurposing of previously approved broad-spectrum antivirals (remdesivir, ritonavir, hydroxychloroquine, interferon) [13,14] and therapeutic doses of corticosteroids (dexamethasone, hydrocortisone, methylprednisolone) [15,16] for high-risk patients while fast-tracking development of vaccines and other novel therapeutics [17]. To that end, great advances in understanding the biology of this new coronavirus and the natural history of the disease have been achieved [18,19]. Moreover, the unprecedented development of multiple COVID-19 vaccines capable of eliciting immunological protection, in less than a year from identification of the causative agent, has been a remarkable success and remains the best hope for ending this pandemic [20].

Despite this incredible progress on COVID-19, many challenges remain post vaccine development including ongoing vaccine deployment, large-scale production and distribution of billions of vaccine doses [21], and uncertainty over the effectiveness of current vaccines against more transmissible new variants [22]. These factors, combined with public hesitation around vaccination, have casted doubt on the likelihood of achieving worldwide herd immunity in the near future [23]. Consequently, other therapeutic strategies to impair virus infection or to counteract further disease spread are still needed, at least until more effective drugs are available or vaccines are distributed and administered to everyone [24].

In the absence of definitive treatment against this new human pathogen, clinical management of hospitalized, severely ill patients remains mainly supportive care, including oxygen and mechanical ventilation, and is based largely on preclinical studies or previous experience with severe acute respiratory syndrome–related coronavirus (SARS-CoV) [25]. Thus, an effective evidence-based therapeutic intervention is urgently needed to reduce the morbidity, mortality, and length of in-hospital stay for patients with COVID-19.

Passive immunotherapy with convalescent plasma (CP), hyperimmune γ-globulin, or artificially produced monoclonal antibodies are beneficial for treatment or prophylaxis of several infections, and these approaches are under investigation as potential therapeutic modalities for the management and prevention of COVID-19 [26]. Passive immunotherapy with human convalescent blood products, in particular CP, is a promising strategy for the prevention and treatment of COVID-19 [27-29]. Although further research is needed to determine the utility of immunotherapy with CP or monoclonal antibodies for the treatment of patients who are symptomatic and potentially for use as postexposure prophylaxis, initial findings in limited clinical trials suggest these interventions are safe and can be effective, particularly when administered early in the course of treatment [29]. Experience suggests that CP therapy could be used as an empirical treatment modality to prevent further progression or promote early recovery in patients who are critically ill with COVID-19 [30,31]. CP has been used safely for decades to treat infectious diseases where no specific treatment is available [32,33]. In the late 19th and early 20th century, CP was given to treat a wide range of viral infections, including diphtheria, polio, measles, mumps, and Spanish influenza A (H1N1) [34-36]. Although no randomized trials were conducted, a retrospective meta-analysis of studies on the use of CP during the Spanish influenza flu pandemic showed a significant decrease in mortality in patients who received CP versus those given plasma from unexposed donors [37]. After World War II, plasma became a valuable pharmaceutical component, which used it for diverse products to successfully treat everything from bleeding disorders to immune deficiencies to hypovolemic shock [38]. Since then, CP has been used in outbreaks of Ebola and other coronavirus diseases including SARS-CoV and Middle East respiratory syndrome–related coronavirus (MERS-CoV) infection with varying efficacy [33]. CP was proven to be efficacious in patients with severe 2009 pandemic H1N1 flu, reducing respiratory tract viral load, serum cytokine responses, length of hospital stay, and patient mortality [39]. CP therapy involves transfusing whole or fractionated plasma, collected from patients that have recently recovered from SARS-CoV-2 infection, to confer passive humoral immunity in people who are infected or at risk of infection [29,40]. Furthermore, CP therapy has advantages over other proposed treatment: it requires low technology (and therefore it can be produced where required independent of pharmaceutical companies), it is low cost and has strong biological plausibility, and it has potential for rapid development and deployment (production is easily scalable as long as there are sufficient donors) [41-43]. Accordingly, on March 24, 2020, the Food and Drug Administration (FDA) approved the use of CP therapy as an emergency investigational new drug to treat patients with serious or immediately life-threatening COVID-19 infections [44]. Subsequently, on August 23, 2020, the FDA issued an Emergency Use Authorization (EUA) for CP for treating COVID-19 [45]. According to the FDA regulation, the plasma must be collected from recovered patients who can donate blood, have had no symptoms for 14 days, and have had negative results on COVID-19 tests. Both single-donor and pooled immuno-globulin products currently prioritize collection of convalescent donor plasma with high levels of neutralizing antibodies. Based on the preliminary data from clinical trials and considering the United States National Institute of Health and FDA recommendation, remdesivir and CP are the most promising potential for COVID-19 treatment [46]. CP for treating COVID-19 is accessible via the regulatory pathways (investigational new drug regulatory pathway). Another is expanded access, also called “compassionate use” emergency Investigational New Drug Application (an investigational medical product), to treat patients [47]. It should be noted that, currently, Regeneron’s REGN-COV2 and Lilly’s LY- CoV555, both of which are cocktail therapies comprising receptor binding domain (RBD)–reactive antibodies, have also been granted EUA for COVID-19 by the FDA [48,49].

On the other hand, systematic reviews have been conducted for current medications that have been used for the treatment of COVID-19. A comparative analysis of three treatment modalities for COVID-19, chloroquine and hydroxychloroquine, CP, and remdesivir, found that each modality had both favorable and unfavorable characteristics, but none showed clear evidence of benefit for early outpatient disease or prophylaxis; in particular, chloroquine or hydroxychloroquine is no longer a viable option [50], while CP therapy appeared to show clinical advantages for inpatient use [14]. Moreover, meta-analysis of the safety and efficacy of various interventions including the three treatments and dexamethasone or lopinavir-ritonavir showed that dexamethasone and remdesivir might be beneficial for patients with COVID-19, but the certainty of the evidence was low to very low, so more trials are needed [51].

Studies are currently underway to evaluate use of CP as treatment for patients with severe COVID-19 and to prevent infection (prophylaxis) in certain high-risk patients exposed to COVID-19. Currently, CP is being given to small numbers of hospitalized patients with severe or life-threatening COVID-19 illness [52]. Several case reports suggest treatment is helpful, but larger studies are still needed. Although there is a lot that is unknown, CP may work best for patients earlier in the disease course [53,54]. Therapy using CP may also be beneficial for prophylaxis against SARS-CoV-2 in individuals who are at high risk; there is considerable interest to leverage CP for frontline health care workers, first responders, other caregivers, and vulnerable individuals with underlying medical conditions [55,56]. This strategy has been previously used in SARS-CoV and MERS-CoV outbreaks [57]. Although the evidence for CP therapy remains inconclusive, preliminary trials for CP suggest that there may be some benefits, and there is growing consensus that CP is an important first-line immunotherapy for emerging viral infections when other specific treatments are not available [58]. Currently, several countries and health institutions are collecting CP for either empirical treatment or clinical trials [55,59]. However, research to date is at a high risk of bias, and randomized control trials are desperately needed to determine the efficacy and safety of this therapeutic option.

There are many ongoing trials and reviews, perspectives, commentaries, and guidelines published every day related to all aspects of COVID-19 CP, ranging from donor selection, plasma collection, testing, and storage to clinical use. In this paper, we sought to review all aspects of CP use for COVID-19, from detection of the level and activity of CP antibodies to appraisal of the quality and meta-analysis of original clinical studies of CP therapy, to characterize the knowledge gap and provide recommendations for future directions.

This systematic review was conducted in accordance with the PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) guidelines [60].

Search Strategy

We searched relevant databases including PubMed, Web of Science, and Embase from June 19, 2020, for published and unpublished trials with no limitations on starting date, with the terms COVID-19 OR SARS-CoV-2 OR “coronavirus* 2019” AND convalescent plasma/ser*; we continued the search and updated the review during the manuscript preparation until October 22, 2020. Both plasma and serum or sera have been used in the literature. In this review, plasma is representative for both terms.

Data Abstraction

Titles and abstracts were screened to determine relevance and, if deemed appropriate, the full article was reviewed. Additional publications were selected from the cross-references listed in the original papers and from the cited articles. Disagreements were resolved by consensus or with another review author. The same strategy was used for data extraction and study appraisal as described later.

Study Eligibility Criteria

Experimental (randomized controlled trials [RCTs], quasi-RCTs, non-RCTs), quasi-experimental (controlled before-after studies, interrupted time series), and observational (cohort, case-control) studies are eligible if they examined CP or serum for prevention, diagnosis, or treatment of COVID-19.

Review articles were excluded unless they were focused on or directly related to CP (eg, passive immunotherapy) for COVID-19. Papers on antibody detection and immunity were also excluded unless specifically related to CP.

Data Extraction and Study Appraisal

All literature search results were screened independently by two reviewers. The commentaries in support of the use of CP for COVID-19 were considered positive, those suggesting improvements in CP treatment were categorized as neutral, and precautions against CP were determined to be negative. The review type was determined according to a typology of reviews by Grant and Booth [61]. The quality appraisal of included clinical studies was conducted using the Effective Public Health Practice Project (EPHPP) Quality Assessment Tool [62]. Specifically, each clinical study was evaluated for the following components: sample selection, study design, identification and treatment of confounders, blinding of outcome assessors and participants, reliability and validity of data collection methods, and withdrawals and dropouts. The overall rate of each study was determined by assessing the six component ratings. Those with no weak ratings and at least 4 strong ratings were rated strong. Those with less than 4 strong ratings and 1 weak rating were considered moderate. Those with 2 or more weak ratings were rated weak.


Studies were analyzed separately according to their design (case report, case series, observational, or randomized trials). Clinical and methodological heterogeneities across the studies were assessed by examining the details of the patients, the baseline data, the interventions, and the outcomes to determine whether the studies were sufficiently similar.

For disease severity, severe COVID-19 is a clinical situation in which the patient has dyspnea, tachypnea (respiratory rate≥30 breaths/minute), blood oxygen saturation≤93% on room air, partial pressure of arterial oxygen to fraction of inspired oxygen ratio <300 PaO2/FiO2<300, or lung infiltrates >50% within 24-48 hours on chest x-ray [63]. Life-threatening disease is defined as respiratory failure, septic shock, or multiple organ dysfunction or failure [63].

Case and randomized controlled studies were combined in meta-analyses using Review Manager (Version 5.4, The Cochrane Collaboration). Data were pooled using an inverse variance method and analyzed using a random-effects model, as this approach accommodates clinical and statistical variations. Odds ratios (ORs) and 95% CIs were used as statistical measures for mortality, clinical improvement, and viral clearance as a dichotomous outcome. Mean and SD were the statistical measure used to describe length of hospital stay. In studies that reported data in medians and IQRs, mean and SD were estimated using the sample size in each study arm, the medians, and the first and third IQRs as demonstrated in the method published by Wan et al [64]. Heterogeneity was determined using the I2 statistic and the chi-square test. High values of both tests (I2>40%, a significant chi-square value with P<.05) demonstrate high levels of inconsistency and heterogeneity.

Overall Findings

As illustrated in Figure 1, we reviewed 438 titles and abstracts and identified 243 manuscripts relevant to five areas of focus or types: (1) original clinical studies; (2) commentary in the form of letter to the editor, correspondence or editorial, brief communication, opinions, perspectives, and viewpoints; (3) review of the use of CP; (4) protocol or guidance for clinical trials or production of CP; and (5) in vitro testing of CP.

A total of 243 articles were included in this review. As summarized in Table 1, they can be stratified as follows: 64 clinical studies (20 case reports, 31 case series, 11 case-control studies, and 2 RCTs), 79 commentary articles, 46 reviews, 19 guidance and protocols, and 35 in vitro testing of CP antibodies.

Figure 1. PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) flow diagram. The literature search was conducted on June 19 and updated on October 22, 2020. The screening, full-text review, and extraction were managed online using Covidence. CP: convalscent plasma.
View this figure
Table 1. Summary of literature.
Article typea and groupArticles, nSummaryReferences
Clinical studies64
Case reportsA single severe or critically ill COVID-19 patient of different ages (6-100 years), either previously healthy or with comorbidities (cancers, organ transplantation, immunodeficiency, hypertension, diabetes, cerebral hemorrhage, cardiopulmary disease, or pregnancy), was successfully treated with one or two doses of CPb (150-250 mL per dose; anti–SARS-CoV-2 IgG titer 1:13.3-1:700) in combination with antiviral or anti-inflammatory drugs (favipiravir and hydroxychloroquine, enoxaparin, methylprednisolone, remdesivir, lopinavir or ritonavir, prednisone), antibiotic therapy (azithromycin, ceftriaxone moxifloxacin, piperacillin, tienam), antifungal medication (fluconazole), or prophylactic low-molecular-weight heparin
  • Al Helali et al 2020 [65]
  • Anderson et al 2020 [66]
  • Bao et al 2020 [67]
  • Cinar et al 2020 [68]
  • Clark et al 2020 [69]
  • Figlerowicz et al 2020 [70]
  • Grisolia et al 2020 [71]
  • Hahn et al 2020 [72]
  • Hartman 2020 [73]
  • Im et al 2020 [74]
  • Jafari et al 2020 [75]
  • Jiang et al 2020 [76]
  • Karataş et al 2020 [77]
  • Khan et al 2020 [78]
  • Kong et al 2020 [79]
  • Mira et al 2020 [80]
  • Rodriguez et al 2020 [81]
  • Soleimani and Soleimani 2020 [82]
  • Xu et al 2020 [83]
  • Zhang et al 2020 [84]
Case series31 clinical studies involving two or more COVID-19 patients of different ages (14-91 years) and disease severity (eg, hospitalized, moderate, severe, or life-threatening), either previously healthy or with comorbidities (cancer, hypertension, immunosuppression, organ transplantation) that were treated with various doses of CP (200 mL to 3 × 200 mL) in addition to supportive care, antiviral therapy, antibiotics, steroids, or anticoagulation treatment.
  • Ahn et al 2020 [85]
  • Abdullah et al 2020 [86]
  • Bradfute et al 2020 [87]
  • Diorio et al 2020 [88]
  • Enzmann et al 2020 [89]
  • Erkurt et al 2020 [90]
  • Fung et al 2020 [56]
  • Gemici et al 2020 [91]
  • Hartman et al 2020 [63]
  • Ibrahim et al 2020 [92]
  • Bobek et al 2020 [93]
  • Jin et al 2020 [94]
  • Joyner et al 2020 [95-97]
  • Liu et al 2020 [98]
  • Maor et al 2020 [99]
  • Naeem et al 2020 [100]
  • Olivares-Gazca et al 2020 [101]
  • Pal et al 2020 [102]
  • Rahman et al 2020 [103]
  • Salazar et al 2020 [104]
  • Shen et al 2020 [105]
  • Tremblay et al 2020 [106]
  • Wei et al 2020 [107]
  • Wang et al 2020 [108]
  • Wu et al 2020 [109]
  • Xi et al 2020 [110]
  • Ye et al 2020 [111]
  • Zhang et al 2020 [112]
  • Zeng et al 2020 [113]
Observational (cohort, case-control studies)11 cohort, case-control studies of a CP treatment group (6-316 patients) and a matched control (12-1430 patients) of severe or life-threatening COVID-19 patients to compare clinical and laboratory outcomes including all-cause mortality, total hospitalization days, and patients’ need for intubation between the two groups.
  • Abolghasemi et al 2020 [114]
  • Duan et al 2020 [115]
  • Hegerova et al 2020 [116]
  • Liu et al 2020 [117]
  • Perotti et al 2020 [118]
  • Rasheed et al 2020 [119]
  • Roger et al 2020 [120]
  • Salazar et al 2020 [121]
  • Xia et al 2020 [122]
  • Xiao et al 2020 [123]
  • Zeng et al 2020 [124]
RCTcTwo RCTs of 86 hospitalized and 103 severe or life-threatening COVID-19 patients randomized at 1:1 ratio for standard of care therapy with and without CP. The primary outcome was mortality and time to clinical improvement.
  • Gharbharan et al 2020 [125]
  • Li et al 2020 [126]
Commentary (correspondence, editorial, letter to the editor, opinions, perspectives, viewpoints)79
PositiveThese are commentaries that supported clinical use and evaluation of CP for COVID-19 treatment based on the unique immunomodulatory properties of CP and historical and current data for its safety and efficacy against coronaviruses including SARS-CoV-2 but suggested limitations, future clinical investigations, and a variety of aspects to be considered for the optimal use of CP for COVID-19 including CP donor selection, CP collection and testing, manufacturing turnaround time, cost and the logistics of storage, distribution, treatment population, and administration timing and dosing.
  • Alghamdi and Abdel-Moneim 2020 [127]
  • Alzoughool and Alanagreh 2020 [128]
  • Borlongan and Sanberg 2020 [129]
  • Cantore and Valente 2020 [130]
  • Casadevall and Pirofski 2020 [34]
  • Casadevall et al 2020 [131]
  • Chen et al 2020 [28]
  • Cheraghali et al 2020 [132]
  • Gazzaruso et al 2020 [133]
  • Farhat et al 2020 [134]
  • Focosi et al 2020 [135]
  • Franchini 2020 [136]
  • Franchini et al 2020 [137-139]
  • Islam et al 2020 [140]
  • Kesici et al 2020 [141]
  • Knudson and Jackson 2020 [142]
  • Kumar et al 2020 [143]
  • McAllister et al 2020 [144]
  • Montelongo-Jauregui et al 2020 [36]
  • Morabito and Gangadharan 2020 [29]
  • Nnaji et al 2020 [145]
  • Pau et al 2020 [146]
  • Perez-Cameo and Marin-Lahoz 2020 [41]
  • Rabelo-da-Ponte et al 2020 [147]
  • Roback and Guarner 2020 [148]
  • Roberts et al 2020 [149]
  • Rubin 2020 [47]
  • Sabando Velez et al 2020 [150]
  • Sahu et al 2020 [151]
  • Sheikh and Baig 2020 [152]
  • Sheridan 2020 [43]
  • Syal 2020 [153]
  • Teixeira da Silva 2020 [154]
  • The Lancet Haematology 2020 [155]
  • Tonn et al 2020 [156]
  • Wong and Lee 2020 [157]
  • Yoo 2020 [158]
  • Zhao and He 2020 [159]
  • Zhu et al 2020 [160]
NeutralThis group of articles highlighted both pros and cons of CP therapy and alternative therapeutic options (eg, equine polyclonal antibodies) for COVID-19, and raised questions regarding neutralizing antibodies, donor selection, collection, testing and qualification of CP, time frame for transfusing CP to recipients, transfusion volume, quality of evidence for the safety, efficacy, and ethics of clinical trials of CP therapy.
  • Tamburello and Marando 2020 [161]
  • Begum and Ray 2020 [162]
  • Bloch 2020 [163]
  • Brown 2020 [164]
  • Casadevall et al 2020 [165,166]
  • Cunningham et al 2020 [167]
  • Dhanasekaran et al 2020 [168]
  • Dzik 2020 [169]
  • Estcourt and Roberts 2020 [170]
  • Farrugia 2020 [171]
  • Fleming and Raabe 2020 [172]
  • Focosi 2020 [173]
  • Garraud 2020 [174]
  • Gniadek and Donnersberger 2020 [175]
  • Han and Zhou 2020 [176]
  • Langhi et al 2020 [177]
  • Lanza and Seghatchian 2020 [178]
  • Mahase 2020 [179]
  • Mahase 2020 [180]
  • Malani et al 2020 [58]
  • Adiwinata Pawitan 2020 [181]
  • Prajapati 2020 [182]
  • Saverino 2020 [183]
  • Stevens et al 2020 [184]
  • Tedder and Semple 2020 [185]
  • Van den Berg et al 2020 [186]
  • Verkerke and Maier 2020 [187]
  • Xi 2020 [188]
  • Zeng et al 2020 [189]
  • Zylberman et al 2020 [190]
NegativeThis group of commentaries suggested that the risks associated with CP use (eg, adverse effects and blood-borne pathogen transmission) outweighed its benefits or other therapeutics for COVID-19.
  • Caccamo et al 2020 [191]
  • Ferreira and Mostajo-Radji 2020 [192]
  • Joob and Wiwanitkit 2020 [193]
  • Sanfilippo et al 2020 [194,195]
  • Wiwanitkit 2020 [196]
Review4646 different types of reviews (a total of 10 review types with unique features in terms of prescribed and explicit methodologies) on CP for treatment of virus infectious diseases (eg, SARSd, MERSe, EBOVf, and H1N1) and COVID-19 with safety and efficacy as main outcomes and recommendations. Some reviews also covered other aspects related to CP use, such as SARS-CoV-2 immunology, mechanism of action, CP donor selection, CP collection, pooling technologies, pathogen inactivation systems, banking of CP, timing and dose of CP treatment, patient selection, risk-benefit analysis, and list of ongoing registered clinical trials.
Rapid review
  • Barone and DeSimone 2020 [197]
  • Majbour and El-Agnaf 2020 [198]
State-of-the-art review
  • Brown and McCullough 2020 [199]
  • Focosi et al 2020 [27]
Scoping review
  • Cao and Shi 2020 [200]
  • Zheng et al 2020 [201]
Review of the evidence
  • de Alwis et al 2020 [202]
  • Fischer et al 2020 [203]
  • Mucha and Quraishy 2020 [204]
Systematic review and meta-analysis
  • Chai et al 2020 [205]
  • Devasenapathy et al 2020 [206]
  • Piechotta et al 2020 [207]
  • Sarkar et al 2020 [208]
  • Sun et al 2020 [209]
  • Abdollahi et al 2020 [210]
  • Annamaria et al 2020 [211]
  • Anudeep et al 2020 [212]
  • Bloch et al 2020 [55]
  • Venkat Kumar et al 2020 [213]
  • Gasparyan et al 2020 [214]
  • Iftikhar et al 2020 [215]
  • Li et al 2020 [216]
  • Lindholm et al 2020 [217]
  • Murphy et al 2020 [218]
  • Sayinalp et al 2020 [219]
  • Subbarao et al 2020 [220]
Mixed studies review
  • Pawar et al 2020 [221]
Systematic review
  • Bakhtawar et al 2020 [222]
  • Chen and Xia 2020 [223]
  • Rajendran et al 2020 [224]
  • Valk et al 2020 [225]
  • Wooding and Bach 2020 [57]
Critical review
  • Focosi and Farrugia 2020 [226]
  • Nagoba et al 2020 [227]
  • Psaltopoulou et al 2020 [228]
  • Tiberghien et al 2020 [59]
Literature review
  • Choi 2020 [52]
  • Khulood et al 2020 [229]
  • Chua Vi Long et al 2020 [230]
  • Ouyang et al 2020 [231]
  • Piyush et al 2020 [232]
  • Rojas et al 2020 [233]
  • Selvi 2020 [234]
  • Sharun et al 2020 [235]
  • Sullivan and Roback 2020 [236]
  • Yigenoglu et al 2020 [237]
Protocol/guidance19These are protocols for clinical trials to evaluate the safety and efficacy of CP in treating COVID-19 patients, guidelines or programs for CP donor selection, CP preparation, laboratory examination, storage, distribution, dose, frequency and timing of CP administration, targeted patients, parameters to assess response to the treatment and long‐term outcome, adverse events, and CP application in resource-limited countries and in pediatrics and neonates.
Preparation/production of CP
  • Accorsi et al 2020 [238]
Protocol for a nonrandomized trial
  • Albalawi et al 2020 [239]
Clinical study and application of CP
  • Al-Riyami et al 2020 [240]
Conceptual framework
  • Albahri et al 2020 [241]
Expert opinion, survey of group members, and review of available evidence
  • Bloch et al 2020 [242]
COVID-19 CP program
  • Blackall et al 2020 [243]
  • Budhai et al 2020 [244]
Study protocol for RCTs
  • Chowdhury et al 2020 [245]
  • Eckhardt et al 2020 [246]
  • Janssen et al 2020 [247]
Perspective document of the Working Party on Global Blood Safety of the International Society of Blood Transfusion
  • Epstein and Burnouf 2020 [248]
  • Epstein et al 2020 [249]
Guidance for treating early to moderate COVID-19 patients with CP
  • Hassan et al 2020 [250]
Initiative for provision of CP
  • Ipe et al 2020 [251]
A pilot program of CP collection
  • Li et al 2020 [252]
Strategy and experience
  • Pei et al 2020 [253]
One arm proof-of-concept clinical trial protocol
  • Perotti et al 2020 [254]
An apheresis research project proposal
  • Seghatchian and Lanza 2020 [255]
Authority guide by Turkish Ministry of Health
  • Yilmaz et al 2020 [256]
In vitro testing of convalescent plasma35
ELISAg with virus antigens (eg, spike and NPh protein sequences) or recombinant ACE-2i as substratesAn ELISA could be a high-throughput competitive assay to detect different antibody types against SARS-CoV-2 in serum and plasma from convalescent patients; to estimate the neutralizing capacity of antispike protein antibodies to block interaction with the human ACE-2 required for viral entry; and to identify candidate sera for therapeutic use. A combination of antigenic targets (NP, spike protein, S-RBDj) may improve the accuracy of IgG detection in CP donors.
  • Amanat et al 2020 [257]
  • Byrnes et al 2020 [258]
  • Gattinger et al 2020 [259]
  • Zhang et al 2020 [84]
  • DomBourian et al 2020 [260]
Pseudovirus capture assay, VNk assay using SARS-CoV-2 strains and Vero-E6 cellsIn vitro evaluation of CP potency for COVID-19 treatment could be measured by its binding capacity to the SARS-CoV-2 spike protein and neutralizing activity against pseudotyped and chimeric viruses and authentic SARS-CoV-2, which is useful to identify donors with high titers for CP for COVID-19 therapy. There were individual differences in the antibody level (neutralizing antibody titers <1:16 to >1:1024) and its changes over 12-60 days since onset of symptoms among representative convalescent patients.
  • Ding et al 2020 [261]
  • Ianevski et al 2020 [262]
  • Schmidt et al 2020 [263]
  • Wang et al 2020 [264]
  • Muruato et al 2020 [265]
Immunoassays for anti–SARS-CoV-2 IgM, IgG, and IgA based on SARS-CoV-2 SPCP collected from adults who met all criteria for donating blood had confirmed COVID-19 by positive SARS-CoV-2 PCRm test and completed resolution of symptoms at least 14 days prior to donation showed a wide range of antibody levels. Total anti–SARS-CoV-2 NP antibody strength correlated with time from symptom resolution to sample collection and symptom duration. There was a decline in the IgG level over a short duration of 10 days. RBDn-specific serum IgG, IgM, and IgA COVID-19 convalescent patients continued to decline from 28 to 99 days after hospital discharge. Anti–SARS-CoV-2 spike protein IgG antibody strength correlated with age and hospitalization for COVID-19.
  • Ragnesola et al 2020 [266]
  • Yang et al 2020 [267]
  • de Assis et al 2020 [268]
  • Dulipsingh et al 2020 [269]
  • Ikegami et al 2020 [270]
  • Ma et al 2020 [271]
PCR-based testsSARS-CoV-2 neutralizing antibodies were detectable as early as 10 days after onset of symptoms and continue to rise, plateauing after 18 days and were not altered by amotosalen and UV-A radiation to inactivate potentially contaminating infectious pathogens in CP. Detectable viral RNA in older COVID-19 patients screened for CP donation even 12-24 days after symptom resolution.
  • Danh et al 2020 [272]
  • Hartman et al 2020 [273]
VN assays based on pseudotyped and live SARS-CoV-2 virus, and anti–SARS-CoV-2 IgM, IgG, and IgA ELISA based on virus antigens and ACE-2The levels of anti–SARS-CoV-2 IgM, IgG, and IgA and the neutralization capacity of CP showed a wide range and changed over time after the onset of COVID-19 symptoms and declined within the first 3 months following diagnosis, suggesting an optimal time period for CP collection. Both could be associated with donor’s age, sex, weight, COVID-19 severity, days between disease onset and plasma collection. There were various degrees of positive correlations (coefficients 0.21-0.87) between the VN and ELISA results. Some commercial ELISA can perform effectively as surrogate assays for predicting neutralizing antibody titres.
  • Abe et al 2020 [274]
  • Beaudoin-Bussières et al 2020 [275]
  • Benner et al 2020 [276]
  • Boonyaratanakornkit et al 2020 [277]
  • Gniadek et al 2020 [278]
  • Patel et al 2020 [279]
  • Harvala et al 2020 [280]
  • Wendel et al 2020 [281]
  • Zeng et al 2020 [282]
  • Dogan et al 2020 [283]
  • Jungbauer et al 2020 [284]
  • Li et al 2020 [285]
  • Ni et al 2020 [286]
  • Robbiani et al 2020 [287]
  • Salazar et al 2020 [288]
  • Weidner et al 2020 [289]
Biophysical antibody profilingCP antibodies can elicit Fc-dependent functions beyond viral neutralization such as complement activation, phagocytosis, and antibody-dependent cellular cytotoxicity against SARS-CoV-2.
  • Natarajan et al 2020 [290]

aThe articles were classified into five types: 64 clinical studies (20 case reports, 31 case series, 11 case-controlled and two RCTs), 79 commentary articles, 46 reviews, 19 guidance and protocols, and 35 in vitro testing of CP antibodies. The details are shown in Table S1 in Multimedia Appendix 1.

bCP: convalescent plasma.

cRCT: randomized controlled trial.

dSARS: severe acute respiratory syndrome.

eMERS: Middle East respiratory syndrome.

fEBOV: Ebola virus.

gELISA: enzyme-linked immunosorbent assay.

hNP: nucleocapsid protein.

iACE2: angiotensin converting enzyme 2.

jS-RBD: spike protein receptor-binding domain.

kVN: virus neutralization.

lSP: spike protein.

mPCR: polymerase chain reaction.

nRBD: receptor-binding domain.

All clinical studies are therapeutic use of CP focusing on safety and efficacy, and they are further reviewed in the following section. The commentaries cover various aspects of CP, ranging from critiques of clinical studies [131,137,148,163,176,189] and literature review [145,221] to the stability of antibodies in CP [156,291], relevant news [180], and a response letter [164], while a majority focused on the safety and efficacy of CP. Most commentaries were in favor of CP therapy for COVID-19, recognizing the need for more high-quality evidence from large and well-designed clinical trials to show its efficacy, and other issues (eg, CP collection) still need to be addressed. Some commentaries proposed alternative or complementary CP-based approaches to COVID-19 that possess fewer risks [178,182] but may not be immediately available for clinical use. Only a few commentaries put more emphases on the potential risks over benefits of CP therapy [191-194,196].

In a particular correspondence, a metadata analysis of the efficacy of CP treatment based on 9 clinical studies (mostly case series) suggested that CP reduced viral loads (risk ratio 0.13, 95% CI 0.09-0.18; P<.001; n=75) and C-reactive protein levels (ratio of mean [ROM] 0.11, 95% CI 0.01-0.86; P<.05; n=42), and improved the clinical status of patients with COVID-19 (ROM 0.53, 95% CI 0.36-0.79; P<.01; n=149) when compared to baseline (date of CP transfusion) [147]. In addition, the effects of CP on C-reactive protein levels and clinical improvement were not associated with the patient’s age and the use of antivirals, antibiotics, and hydroxychloroquine. Several commentary papers and reviews advocated for the rationale of developing fast access to CP collection and treatment of patients with COVID-19 [34,47,59,148,199,229]. Among the reviews, most were descriptive overviews of existing literature and recommendations for clinical use and trial without any search strategies. Few were conducted following the PRISMA guidelines [222,224,225]. It is noteworthy that 1 systematic review and meta-analysis was on the safety and efficacy of CP therapy for other severe respiratory viral infections to provide indirect evidence for CP therapy for COVID-19 [206], and another 2 systematic reviews and meta-analyses were on completed and ongoing clinical studies on the safety and efficacy of CP or hyperimmune immunoglobulin transfusion in the treatment of COVID-19 [207,208]. One review and meta-analysis included 20 studies (1 RCT, 3 controlled nonrandomized studies of interventions, 16 noncontrolled nonrandomized studies of interventions) with 5443 participants [207]. The meta-analysis of 4 controlled studies (1 RCT and 3 controlled nonrandomized studies of interventions) with 339 patients could not support any effects of CP treatment on all-cause mortality at hospital discharge, time to death, or improvement of clinical symptoms at 7 days. The review also investigated the safety of CP based on 14 studies (5201 participants, with 5000 participants from 1 noncontrolled nonrandomized studies of intervention) and found very low-certainty evidence for safety. The review was recently updated, which included 19 studies with 36,081 patients treated by CP, and made the same conclusion [205]. The other review included 7 studies, including 2 RCTs and 5 cohort studies, with a total of 5444 patients [208]. The meta-analysis indicated that CP therapy reduced mortality and increased viral clearance and clinical improvement. It confirmed the safety of CP transfusion with very low incidence of serious adverse events. However, the risk of bias and quality assessment in both reviews indicated that the evidence for the efficacy and safety of CP therapy was of low quality, suggesting the need for a large well-designed RCT. In addition, a survey has been conducted for current registered clinical trials of CP therapy for COVID-19, including a description of their characteristics such as study design, patient populations, outcomes, eligibility criteria for CP donors, CP collection, antibody titer, and CP dose [218].

Protocols, programs, and standards have been developed to select donors and collect, process, characterize, store, distribute, and apply CP to patients in need [238,240,242,250], and to conduct clinical trials [239,246,247,254]. Regional and national programs for COVID-19 CP have been established [243,244] as well as a multi-criteria decision-making frame for both CP donor and receipt selection [241].

Some key findings and implications from the in vitro testing studies of CP antibodies should be considered: a variety of methods have been developed to measure CP antibody titers including gold standard neutralization assay using living SARS-Cov-2 [261,262]; enzyme-linked immunosorbent assay (ELISA) using the antigens derived from the virus, mostly in a microplate platform [257,258] and a few in lateral flow [266], microsphere [267], and microarray platforms [268]; and other methods (eg, polymerase chain reaction [PCR] tests) [272,273]. A number of studies showed a wide range of levels and neutralizing activities of anti–SARS-CoV-2 [264,267,289]. The neutralizing antibody levels declined within the first 3 months following diagnosis, suggesting a short optimum time window for the collection of CP with high neutralizing antibody titers [280]. A significant decrease was also observed in the antibody binding to the spike protein of SARS-CoV-2 and neutralizing capacity of plasma from convalescent donors at 6 and 10 weeks after symptoms onset [261]. The short duration of neutralizing antibody titers within months may have important implications for immunity and ongoing efforts to deploy CP for prevention and therapy of COVID-19 [165]. There is a significant correlation to various extents between ELISA-measured immunoglobulin (IgG) titer and neutralizing antibody titer [87,257,274,276,278-280,283-285,288,289]. However, the ELISA-determined anti–SARS-CoV-2 IgG did not always inhibit the virus receptor binding [259]. Antibody binding to SARS-CoV-2 spike glycoprotein as measured by pseudovirus capture assay did not always translate into neutralization [261].

Highly sensitive and specific platforms for the detection of anti–SARS-CoV-2 antibodies are becoming increasingly important for evaluating potential CP donors and identifying individuals with seroconversion [292]. Various platforms demonstrate significant correlations with a SARS-CoV-2 plaque reduction neutralization assay, suggesting their use for screening of individuals who have recovered from SARS-CoV-2 infections. Notably, a novel multiplexed solid-phase chemiluminescence immunoassay has been developed and commercially available from Meso Scale Discovery for simultaneous detection of IgG binding to four SARS-CoV-2 antigens (trimeric spike, spike RBD, spike N terminal domain, and nucleocapsid antigen) and the quantification of antibody-induced angiotensin-converting enzyme 2 (ACE-2) and ACE-2–binding inhibition (pseudo-neutralization assay) [293].

In addition to neutralization and immune assays, biophysical and functional evaluation of CP showed that it may have diverse antiviral effects against SARS-CoV-2 beyond neutralization, namely, antibody-dependent cellular cytotoxicity, phagocytosis, and complement activation [290]. Moreover, CP could act not only on the viral infection but also on the antithrombin deficiency to reduce thromboembolic events [133].

Findings of Clinical Studies

As summarized in Table 2, there are considerable heterogeneities among the clinical studies in terms of the populations, the amount of CP received, and a variety of comparators. The CP therapy studies differed in the following aspects: patient demographics (eg, age, gender, and comorbidities), donors’ selection (ie, age, gender, diagnosis of SARS-CoV-2 infection and of recovery, and anti–SARS-CoV-2 antibody titer required for plasma donation), plasma collection and biologic qualification (number, volume and frequency of donations, infectious disease markers, and pathogen inactivation), and treatment and disease characteristics (dose and timing of administration, stage of the disease at which to start CP treatment).

Table 2. Summary of original clinical studies of CP therapy for COVID-19. The studies were stratified according to the study design.
Study design and studiesPopulationDetails of CPaInterventions and comparisonsOutcomes/main findingsAdverse events related to CP therapy
Case report

Al Helali et al 2020 [65]A previously healthy male 55 years of age with severe COVID-19Not reportedAbout 300 mL CP was transfused over 1 h in addition to other therapeutics: favipiravir, hydroxychloroquine, enoxaparin, paracetamol, diphenhydramineA significant radiological and clinical improvement in a few days after CP transfusion and negative PCRb test for COVID-19 in <48 h and discharged 12 days post transfusionNo significant adverse effects

Anderson et al 2020 [66]A pregnant critically ill female 35 years of age with COVID-19 and past medical history for type 2 diabetes mellitus, asthma, and class III obesityNot reportedOne unit of CP on the day of admission at ICUc and supportive care and therapeutic agentsDischarged on day 14 with no further issues afterward and continuing antenatal care with both primary obstetric office and maternal fetal medicine specialistsNot reported

Bao et al 2020 [67]A critically ill man 38 years of age infected by SARS-CoV-2 and had cerebral hemorrhageNot reported150-200 ml CP of type A Rh positive was given twice 9 days after hospital admission in addition to antiviral and antibacterial treatmentBoth SARS-CoV-2 nucleic acid tests were negative (24 h interval) 2 days after the transfusion, and the patient’s symptoms gradually stabilizedNot reported

Cinar et al 2020 [68]A male patient 55 years of age with severe COVID-19 and active myeloid malignancy, disseminated tuberculosis, and kidney failureCollected using Trima Accel Automated Blood Collection System from a donor who had previously recovered from COVID-19 and met universal donation criteria, anti–SARS-CoV-2 IgG titer 6.6200 mL of CP on fifth day of symptom onset and another 200 mL of CP at ICU, in combination with antiviral and anticytokine drugsSARS-CoV-2 was negative, discharged from the hospital with full recoveryNo adverse reaction or complication

Clark et al 2020 [69]Immunocompromised woman 76 years of age with persisting COVID‐19 following therapeutic lymphocyte depletionNot reportedCP transfused at day 50 after symptom onset over 2 days (200 mL/day) in addition to treatment with lopinavir/ritonavir and prednisoneRapid improvement in health condition, allowing definitively withdrawing oxygen, apyrexia ensued, and negative SARS-CoV-2 test; discharged on day 69No adverse events 

Figlerowicz et al 2020 [70]A girl 6 years of age with severe COVID-19CP inactivated using methylene blue with anti–SARS-CoV-2 IgG at a titer of 1:700CP transfused once in a 200-mL dose at 5 weeks from the beginning of the disease and treatment with antiviral drugs and immune modulators, antibiotics, and antifungal drugsSARS-CoV-2 was negative for the next 3 weeks after CP therapy. The hematologic parameters did not improve after SARS-CoV-2 elimination.No adverse events

Grisolia et al 2020 [71]A woman 29 years of age at 24 2/7 weeks of gestationNot reportedThe patient was transfused with 300 mL of CP on day 7 from onset of symptoms and another 300 mL of CP on day 12, and treated with antibiotics, low-molecular-weight heparin, hydroxychloroquine, and methylprednisoloneThe patient’s clinical condition rapidly improved as shown by normalization of laboratory tests, body temperature, O2 saturation, and vital signs within 3 days of the second CP transfusion, discharged 13 days after admissionNo adverse effects

Hahn et al 2020 [72]A previously healthy man in his 70s with severe COVID-19 admitted to ICUObtained from two blood donors with one being diagnosed with high-level anti–SARS-CoV-2 IgG antibodyA total of 900 ml of CP was transfused at a slow infusion rate on day 31 after admission and treatment with a respirator, muscle relaxants, and antibioticsThe patient became afebrile and was tested negative for SARS-CoV-2 the following day after CP therapy, gradually improved and was weaned from the ventilator and discharged alive from the ICU on day 63Not reported

Hartman et al 2020 [73]A man 62 years of age with a history of moderate persistent asthma, sinus bradycardia, chronic obstructive pulmonary disease, and newly diagnosed COVID-19Not reportedThe patient received 217 mL of CP with no other interventions at the time estimated 7 days after onset of symptoms (cough and shortness of breath)The patient showed rapid improvement in symptoms and electrocardiogram findings, and was discharged 36 hours after the transfusionNot reported

Im et al 2020 [74]A man 68 years of age with severe COVID-19A donor with ABO blood group A (Rh-positive) incompatible with the patient ABO blood group B (Rh-positive)250 mL of CP at 16 days after symptom onset for 2 consecutive days with mechanical ventilation and ECMOd, steroid, heparinization, and antibiotic treatmentThe patient showed clear improvement in respiratory distress and fever symptoms for 3 days after the CP transfusion; discharged without any detectable virus or other complicationsNo evident acute adverse effect

Jafari et al 2020 [75]A woman 26 years of age with a twin pregnancy at 36 weeks and 1 day gestation with confirmed COVID-19Not reportedOne unit of CP was transfused on the sixth day after hospital admission in addition to favipiravir and oxytocine The patient showed dramatic clinical and radiologic improvements and was discharged 2 weeks after admission with no infection of the newbornsNot reported

Jiang et al 2020 [76]A kidney transplant female recipient 70 years of age with immunosuppression; severe COVID-19; and a history of chronic bronchitis, hypertension, and hyperlipidemiaCollected by apheresis from a donor who had recovered from SARS-CoV-2 infection for >14 days, with an ELISAe antibody titer >1:1000200 mL CP was administered at day 4 and 11 after admission in addition to treatment with moxifloxacin, piperacillin, methylprednisolone, tienam, and fluconazoleThe patient’s body temperature became normal and chest CTf was significantly better than at admission, and the patient was discharged on day 30Not reported

Karataş et al 2020 [77]A man 61 years of age with a history of ASCTg for lymphoma with persistent positive tests for SARS-CoV-2 RT-PCRh and feverObtained using Trima Accel Automated Blood Collection System from a donor satisfying universal donation criteria and recovered from COVID-19 disease; ELISA IgG titer 13.3CP transfusion on the 40th day of the infection (dose not specified)After the CP transfusion, his fever resolved after 3 days. He was discharged from the hospital on the 78th day of hospitalization; viral shedding remained positive as demonstrated by RT-PCRNot reported

Kong et al 2020 [79] A mild COVID-19 male 100 years of age with a 30-year record of hypertension, abdominal aortic aneurysm, cerebral infarction, prostate hyperplasia, and complete loss of cognitive function for the preceding 3 yearsCollected via plasmapheresis from a donor who had recovered from COVID-19 for more than 2 weeks and had a SARS-CoV-2 S-RBDi–specific IgG titer >1:640The patient received CP twice: 200 ml on the seventh day of hospitalization and 100 ml on the 11th day of hospitalizationPatient’s viral load decreased significantly, by a factor of ~18, 24 h after the first transfusion of convalescent plasma and then became undetectable after the second, discharged on day 13 of hospitalizationNot reported

Mira et al 2020 [80]A male patient 39 years of age with severe COVID-19 and XLAj, receiving monthly immunoglobulin replacement therapyIgG antibodies against either the spike or nucleocapside viral proteins with a titer ≥1:320200 mL, single dose, on day 23 after admissionAfter 24 h of infusion, fever ceased without subsequent reappearance and with progressive improvement of asthenia. After 48 h of infusion, no detectable virus in qPCRk from nasopharyngeal exudateNot reported

Soleimani and Soleimani 2020 [82]A woman 30 years of age (gravid 3, parity 2) at her 21 and 2/7 weeks gestation with ARDSl caused by SARS-CoV-2 infectionNot reportedCP was administered in addition to lopinavir/ritonavir and azithromycin and early methyl prednisolone therapyA mild clinical improvement and decrease in inflammatory markers; normal growth of the fetusNot reported

Xu et al 2020 [83]A man 65 years of age with severe COVID-19Collected from two convalescent patients; no details providedCP was given at a 400-mL dose on day 1 and 2 after admission, and hydroxychloroquine was orally administrated for a weekOn day 11 after CP transfusion, temperature returned to normal and mechanical ventilation was withdrawn, the RNA test remained positive in throat swab, and CT revealed severe pulmonary lesionsNo apparent side effects 

Zhang et al 2020 [84]A critically ill female 64 years of age with hypertension and diabetesCollected by apheresis from a male 37 years of age with blood type O at 36 days after symptom onset and 17 days after discharge; CP IgG titer >1:320 by ELISA200 mL CP on day 17 of hospitalization while receiving invasive mechanical ventilationThe patient did not require mechanical ventilation 11 days after plasma transfusion and was transferred from ICU to a general wardNo adverse event
Case series

Ahn et al 2020 [85]A previously healthy man 71 years of age and a woman 67 years of age with a medical history of hypertension, both diagnosed with severe COVID-19Obtained with Spectra Optia apheresis system from a male donor in his 20s who had recovered from COVID-19 for 21 and 18 days, respectively, and met the blood donor eligibility criteria for plasma donation. ELISA optical density ratio for anti–SARS-CoV-2 IgG was 0.586 and 0.532 (cutoff value 0.22)A total 500 mL of CP was divided into two doses and given over 1 hour for each dose at 12-hour intervals after 22 days from the onset of symptoms in case 1 and 7 days in case 2SARS-CoV-2 became negative in both cases: case 1 underwent a tracheostomy and currently was successfully weaned from the mechanical ventilator; case 2 was successfully extubated and discharged from the hospital on day 24No adverse reaction occurred after the administration of CP

Abdullah et al 2020 [86]A male 46 years of age and a male 56 years of age, both with hypertension and severe COVID-19Collected from a recovered moderate COVID-19 patient after performing necessary investigations for donor plasma (hemoglobin level and viral screen) but not antibody testsDeteriorated despite supportive care and antiviral therapy: 200 mL of CP at day 3 of hospitalization (day 7 after symptom onset) in case 1; day 10 of hospitalization (day 13 after symptom onset) in case 2Improve clinically 4 days and 70 h after CP, discharged from the hospital 16 and 21 days after admission with three consecutive negative RT-PCR tests each with at least 24 h apartNot reported

Bradfute et al 2020 [87]12 hospitalized COVID-19 patients (8 males and 4 females) with a median age of 52 (range 39-91) years, 9 obese patients, 10 patients in the ICU, and 2 on the general wardCollected by apheresis from donors ≥28 days after positive PCR test, with complete recovery from COVID-19 and a median of neutralizing antibody titer of 1:40 (range, undetectable to 1:160)Patients received one unit (200 mL) CP at a median of 8.5 (range 6-16) days after the onset of symptoms and a median 3.5 (range 1-10) days after hospitalizationTemporal increases in neutralizing antibody titers and IgG/IgM levels, gradual decreases in viral loads, with two deaths within 14 days after CP transfusionNo serious adverse events

Diorio et al 2020 [88]Four critically ill children with COVID-19; 14-18 years; female; varied antibody titer levels pretransfusionCollected from donors proven positive for SARS‐CoV‐2 by a laboratory test; and either ≥14 days from symptom resolution with a repeat negative test for SARS‐CoV‐2 or ≥28 days from symptom resolution without the repeat test. RBD-specific IgG titer <1:160 to >1:6000200-220 mL of CP at 7-14 days after symptom onset1 died; 2 showed no clinical improvement; 1 recoveredNo emergent adverse events related to CP infusion

Enzmann et al 2020 [89]16 critically ill COVID-19 patients with most (12 patients) underlying cardiovascular diseaseNot reportedNot reportedIn-hospital mortality rate was 31% and median length of hospital stay was 19 (8-36) daysNo apparent adverse effects

Erkurt et al 2020 [90]26 (8 females and 18 males) severe COVID-19 patients (mean age 67.4, SD 15.5 years)Collected via apheresis ≥14 days after complete recovery from the eligible blood donors who had mild or moderate COVID-19 with positive antibodies200 mL of CP was administered at a mean 13.87 (SD 6.5) days after admission in addition to supportive treatment, hydroxychloroquine, azithromycin, and favipiravirThe patients who did not need mechanical ventilation improved with CP treatment, while 6 of 17 patients on mechanical ventilation were deadNo severe adverse reactions

Fung et al 2020 [56]4 immune-suppressed patients (males: two were aged 42 years and one was aged 62 years; female: one aged 65 years) with or at risk of progression to severe or life-threatening COVID-19Collected per FDAm guidance from donors with confirmed COVID-19 and resolution of symptoms within 14-28 days and a negative PCR test or >28 days without a PCR test; ELISA anti–SARS-CoV-2 spike protein IgG titer >1:400Approximately 200 mL of CP was transfused at 4-27 days following symptom onsetAll patients were clinically improved, with 2 discharged home and fully recovered, and 2 discharged to skilled nursing facilitiesNo adverse reactions

Gemici et al 2020 [91]40 consecutive patients (median age 57.5 years and 72.5% male) with severe COVID-19Collected from eligible blood donors recovered from COVID-19 with negative laboratory results and symptom free for ≥14 daysPatients received a median of 2 (range 1-3) units of CP at median time of 5 days from the diagnosis in addition to antiviral therapy90% of patients who received CP outside ICU totally recovered at a median of 9 days after the transfusion, and half of the patients treated in ICU were free of mechanical ventilationNo TRALIn or severe allergic reactions

Hartman et al 2020 [63]16 (7 female) severe and 15 (3 female) life-threatened patientsCollected from a local donor recruitment and referral programDose and timing not reportedRespiratory support requirements began on or about day 7 following CP transfusion, especially in the severe patientsNot reported

Ibrahim et al 2020 [92]38 hospitalized, severely (n=16) or critically ill patients (n=22) with confirmed COVID-19 (mean age 63, SD 12 years; 18 female); 31.5% had three or more comorbidities, with 68% having hypertension and 47% having diabetesCollected by apheresis from adults who were confirmed positive and had recovered from SARS-CoV-2 with negative PCT test for the virus and had total anti–SARS-CoV-2 titer >1:320ABO-compatible CP was given in two consecutive 200-mL infusions (mean 18.7, SD 9.0) days following symptom onset. Another unit of CP was given to those with undetectable anti–SARS-CoV-2 antibodies.24 (63%) recovered and were discharged from the hospital, and 14 (37%) died. The survival patients received CP earlier in their course of disease (mean 15.3, SD 6.9 days) and hospital stay (mean 8.4, SD 6.8 days) compared to those who died with mean durations of 24.5 (SD 9.6) days and 16.6 (SD 9.5) days, respectively.No adverse effects except for a transient transfusion reaction (fever and hematuria) within 2 h of CP infusion in 1 patient 

Bobek et al 2020 [93]2 critically ill Hungarian patients (males 59 and 72 years of age) with COVID-19, hypertension, and cardiovascular diseaseCollected by plasmapheresis from recovered COVID-19 patients who had been asymptomatic for at least 2 weeks, negative PCR tests, and IgG-type antibody detectable by ELISA3 × 200 mL of CP with the first dose administered on the fourth day of the patient’s ICU mechanical ventilationBoth showed improved oxygenation and inflammatory decreased markers, and were weaned from mechanical ventilation within 2 weeksNo severe adverse effects

Jin et al 2020 [94]3 patients (males 10, 24, and 40 years of age) with XLA, hospitalized for COVID-19CP containing antispike protein titer 1≥:320Two units of 200 mL ABO-compatible CP were given on days 16, 22, or 44 of illness when there was minimal improvement on other therapiesVarious clinical and laboratory improvements including increases in antibody titers; discharged within days after CP transfusionNot reported

Joyner et al 2020 [95]5000 hospitalized adults (median age of 62) with 81% having severe or life-threatening COVID-19 and 66% admitted to ICUABO-compatible CPCP dose of 200-500 mLThe incidence of SAEso was less than 1%, and the mortality rate at the seventh day after CP transfusion was 14.9%Of 36 SAEs, 7 and 11 incidents of TACOp and TRALI, respectively, were judged as related to CP transfusion

Joyner et al 2020 [96]20,000 hospitalized adults (aged 20-80 years) with severe or life-threatening COVID-19 ABO-compatible CP with no minimum neutralizing antibody titer level donated by recently recovered COVID-19 survivorsCP dose of 200-500 mL141 SAEs classified as transfusion reactions were reported (<1% of all transfusions); 38 thromboembolic or thrombotic events and cardiac events were related to the transfusion. The mortality rate at the seventh day after transfusion was 13.0%.Of 141 SAEs, there were 36 reports of TACO, 21 reports of TRALI, and 21 reports of severe allergic transfusion reaction

Joyner et al 2020 [97]35,322 hospitalized patients with (or at risk of) severe or life- threatening acute COVID-19 and a diverse representation of gender, age, weight status, race, and ethnicityCollected from recently recovered COVID-19 survivors without symptoms for ≥14 days, and the antibody levels in the units collected were unknown at the time.All patients were treated with at least one unit (~200 mL) of CP with the option to administer additional doses if clinically justified in addition to adjunctive COVID-19 medicationsA gradient of 7- and 30–day mortality associated with higher IgG levels in CP and early CP transfusion within 3 days of COVID-19 diagnosisReported in Joyner et al 2020 [96]

Liu et al 2020 [117]3 critically ill male patients with COVID‐19 (42, 56, and 58 years of age; two healthy; one with hypertension)Collected from COVID-19 survivors who had fully recovered and tested negative for the virus and a total anti–SARS-CoV‐2 IgG titer of 160Patients were transfused with 200-225 mL CP between 20 and 30 days after disease onset at the critical illness stage in addition to standard careNo therapeutic effect of CP was observed in any of the patientsNot reported

Maor et al 2020 [99]49 patients (median age 64.0, IQR 50.5-76.0 years; 35 males) with moderate and severe COVID-19 and comorbidities (diabetes and hypertension) in one-third of the patientsCollected by apheresis procedure from recovered COVID-19 patients eligible for plasma donation and >14 days since the last negative PCR test; neutralizing antibody titer 1:20-1:2560The first dose of 200 mL CP was transfused at a median of 10.0 (IQR 4.0-14.0) days after PCR diagnosis, followed by a second unit of 200 mL 24 h later, in addition to various standard of careAt day 14 after the first CP dose, 24 patients improved, 9 died, and 13 were ventilated. More patients improved when treated with CP containing higher antibody levels or earlier.No serious adverse events except that one developed a rash that responded to antihistamine therapy

Naeem et al 2020 [100]3 kidney transplant recipients with COVID‐19 treated with CP (1 female 65 years of age admitted to the general medicine service and a female aged 35 years and a male 36 years of age in the ICU)Collected from donors at local and regional blood centers One or two units of CP were given on day 2, 4, or 7 after hospital admission, in addition to immunosuppressant/ antiviral/antibioticAll showed clinical improvement and were discharged 9, 16, and 25 days after hospital admission with no evident infectious complications1 patient experienced acute chest pain and dyspnea but improved over the following 12-24 h.

Olivares-Gazca et al 2020 [101]10 male severe COVID-19 patients with a median age of 53 (range 27-72) years and comorbidities (diabetes, hypertension)Obtained by apheresis from 5 donors (2 females) with a median age of 35 (range 24-52) years and two negative PCR tests in a 24-h interval 10 days after the resolution of COVID-19 symptomsEach patient received 200 mL of ABO-compatible CP and other therapies (eg, steroids or hydroxychloroquine)Improvement in overall respiratory function and clinical condition over a period of 8 days, with 6 discharged and 2 diedNo side effects

Pal et al 2020 [102]17 critically ill patients (mean age 56, range 24-81 years; 10 males) with COVID‐19 and most patients had multiple medical comorbidities, including 6 with hematological malignanciesCollected from donors 18-56 days following full recovery from COVID-19 with anti–SARS-CoV-2 spike protein IgG titers 1:400-1:6400 as measured by ELISAA single unit of 200 mL CP was given at an average time of 12 (range 4‐41) days from illness; 3 patients received two units roughly 8 days apart in addition to other COVID-19 treatment and chemotherapy as requiredAll patients showed a decline in oxygen needs and ventilatory support with most effects seen in patients when CP was administered early in their disease courseNo adverse events except a fever during transfusion in 1 patient, resulting in infusion of only 100 mL

Rahman et al 2020 [103]13 SOTq recipients (median age 51, range 20‐75 years; 8 males) with severe COVID-19 and comorbidities (eg, hypertension and diabetes)Collected from eligible blood donors with anti–SARS-CoV‐2 spike protein antibody titers ≥1:320 as measured by ELISAAll patients received two ABO-compatible units of CP, for a total of 500 mL, at a median time of 8 days from symptom onset and additional therapies (hydroxychloroquine alone or in combination with azithromycin, steroids, anticoagulation, and immunosuppression)8 patients had de-escalating oxygenation support by day 7 post CP. 9 patients were discharged, 1 still hospitalized, and 3 patients died ~3 months after the CP transfusion.No apparent transfusion-related adverse reactions

Salazar et al 2020 [104]25 patients (median age 51 years) with severe or life-threatening COVID-19 and one or more underlying chronic conditionsObtained from donors eligible according to standard blood donor criteria, confirmed SARS-CoV-2 infection and symptom free for 14 days, and tested negative for SARS-CoV-2 by RT-PCR; ELISA IgG titer ranged from 0 to 1350One 300-mL dose of CP at a median time of 10 days from symptom onset and concomitant anti-inflammatory and antiviral treatments, and 1 patient received a second dose 6 days after the initial transfusionBy day 14 of CP transfusion, 19 (76%) patients had clinical improvement and 11 were dischargedNo adverse events within 24 h after transfusion. 1 patient developed a morbilliform rash 1 day after transfusion that lasted for several days.

Shen et al 2020 [105]5 critically ill patients (age range 36-65 years; 2 female) with laboratory-confirmed COVID-19, rapid progression, and continuously high viral load despite antiviral treatmentObtained from 5 patients who recovered from COVID-19; anti–SARS-CoV-2 IgG titer >1:1000 as determined by ELISA and a neutralization titer >40ABO-compatible CP was administered at a dose of 200-250 twice (400 mL in total) between 10 and 22 days after admissionImprovement in their clinical status as indicated by declined viral load, body temperature reduction, improved PaO2 /FiO2, and chest imagingNot reported

Tremblay et al 2020 [106]24 patients with cancer and severe or life-threatening COVID-19 (median age 69, range 31-88 years; 14 males), some having other comorbidities (eg, hypertension in 15 patients)Collected via plasmapheresis, spike protein-directed ELISA antibody titers ≥1:320Two units (250 mL) of ABO-compatible CP were transfused at 3 (IQR 2-7) days from admission in addition to cancer‐directed treatment and COVID-19–specific therapies (hydroxychloroquine, azithromycin, remdesivir, and tocilizumab)Marked variability in both the timing and degree of improvement or worsening of oxygen requirement; 13 discharged; 10 deaths3 patients experienced febrile nonhemolytic transfusion reactions 

Wang et al 2020 [108]5 critically ill COVID-19 patients (median age 56, IQR 50-62 years) admitted to ICU with a persistent (>30 days) positive nucleic acid test for SARS-CoV-2 and underlying chronic comorbidities, including hypertension and diabetesCollected from the recently cured patients whose antibody titers were above 1:640200 mL of cross-matching CP was transfused over 15 min initiated at a median of 37 (IQR 34-44) days from the onset of symptoms. In total, 3 patients received 400 mL and the other 2 received 1200 mL; all received antibiotics, antiviral, and anti-inflammatory agents.Within 6 days after CP therapy, all patients became negative for two consecutive nucleic acid tests. Additionally, 4-9 days following the CP, 3 patients showed resolution of pulmonary lesion. 2 recovered and 3 died.No adverse reactions

Wei et al 2020 [107]2 COVID-19 patients (males aged 50 and 81 years, the latter with type 2 diabetes mellitus, hypertension, and aortic dissection) with long-term positive viral infectionNot reportedOne or two 200-mL doses of CP were administered >8 weeks after symptom onset; other therapeutics: interferon, arbidol, chloroquine phosphate, and ritonavir-boosted danoprevirSubstantial improvement as confirmed by CT scan and discharged after three consecutive negative nucleic acid tests Not reported

Wu et al 2020 [109]27 adult patients with prolonged infection for a median of 44 (IQR 30-47) days between symptom onset and last positive test of SARS-CoV-2 before CP therapy (median age 64, IQR 57-72 years; 55.5% males), some with chronic diseasesCollected from donors (without transfusion-related infectious diseases who recovered from COVID-19) >3 weeks after symptom onset and >10 days after discharge; neutralizing antibody titer >1:160The patients were treated with a median of 400 (IQR 200-600) mL CP at a median of 45 (IQR 3549) days after symptom onset and other therapeutics: antivirals, antibiotics, corticoid, or immunoglobulinThe patients showed pulmonary imaging improvement (within 5-8 days) and viral clearance (18 patients) 15 days after the CP transfusion, and 3 died within 60 daysNo transfusion-related adverse reactions

Xi et al 2020 [110]3 severe COVID-19 patients with comorbidities (hypertension, liver injury, and hepatitis B)Collected from 2 recovered patients with high levels of IgG (>30 AU/mL) and IgG titer >1:8050 mL twice with a 2-day interval and other treatments with noninvasive mechanical ventilation and antiviral, antibacterial drugs, and traditional Chinese medicineThe CT images, blood gas analysis, and symptoms improved after CP therapy. All recovered after 16-18 days of hospitalization.No adverse event

Ye et al 2020 [111]6 laboratory‐confirmed critically ill COVID‐19 patients (mean age 58, SD 16.4 years; 3 male)Collected from patients at least 3 weeks following disease onset, two consecutive negative RT-PCR tests, and seropositive for anti–SARS‐CoV-2 IgG and IgMOne to three doses of ABO-compatible CP (200 mL/dose) at 6-31 days after admission. Each transfusion was administered over a 30‐minute period.A resolution of ground‐glass opacities and consolidation in 5 out of 6 patients and an elimination of the virus in 2 in the following days of CP therapyNo adverse events

Zhang et al 2020 [112]4 critically ill patients infected with SARS-CoV-2 (age: 31-73 years; 2 male)Prepared from recovered patients without detailsOne to eight doses of CP (200-2400 mL in total) 11-41 days after admission in addition to antiviral therapyThe time from transfusion to negative RT-PCR test results ranged from 3 to 22 days. 3 were discharged from the hospital, and 1 remained in ICU up to the time of this writingNo adverse events

Zeng et al 2020 [113]8 patients (4 males, median age 65 years) with severe or critical COVID-19; 5 patients had coexisting chronic diseasesCollected from seven donors (median age of 37 years) who had mild or moderate COVID-19 with no comorbidities and were at a median day of 11 from discharge; neutralizing antibody titer 1:255-1:1576ABO-compatible and cross-matched CP were administered at one (3 patients) or two doses of 100-200 mL of CP within 24 h between 9 and 34 days following the onset of symptoms6 of 8 patients showed an improvement in oxygen support status within 5 days from CP treatment, partial resolution of pulmonary lesions, and decreased viral loadNo adverse events
Observational (cohort, case-control) studies

Abolghasemi et al 2020 [114]115 CP treatment group with an average age of 54.4 years, and 74 control group– matched by age, gender, underlying diseases (hypertension and diabetes), and COVID-19 severitySelected from clinically and laboratory-confirmed recovered patients of COVID-19 who were between the ages of 18-60 years and had no remaining symptoms of COVID-19 infection for at least 14 days; ELISA antibody titer cutoff index >1.1One unit of 500 mL was infused in <3 days of hospital admission (≤7 days since illness onset), followed by another unit if the patient did not show any improvement after 24 hMore discharged patients (98.2 % vs 78.7 %), shorter hospital stay (9.54 vs 12.88 days), and less requirement for intubation (7% vs 20%) in the CP group than the control groupNo adverse effect

Duan et al 2020 [115]10 severe COVID-19 patients (6 males and 4 females) with a median age of 52.5 years in comparison with a historic control group of 10 patients matched by age, gender, and severity of the diseasesCollected by apheresis using a Baxter CS 300 cell separator from 10 donor patients who recovered from COVID-19 at 3 weeks after illness and 4 days after discharge and two consecutively negative results of sputum SARS-CoV-2 by RT-PCR assay (1-day sampling interval) neutralization activity of >1:640One dose (200 mL) of CP at the median time of 16 days from onset of illness in combination with antiviral, antibiotic or antifungal treatment, or glucocorticoid therapyImproved clinical symptoms and paraclinical criteria within 3 days after CP, varying degrees of absorption of lung lesions for all patients within 7 days, as compared to 3 deaths, 6 cases in stabilized status, and 1 case of improvement in the control group (P<.001)No SAEs or safety events; 1 patient showed an evanescent facial red spot

Hegerova et al 2020 [116]20 patients (median age 60, range 29-95 years) with severe or critical COVID-19 treated with CP under an expanded access protocol, as compared with 20 matched controls with regard to age, number of comorbidities, and severity of illnessCollected from patients aged from 29 to 79 years who recovered from COVID-19 (symptom free) for >28 days without hospitalization, most showing anti–SARS-CoV-2 IgGOne unit of ABO-compatible CP was administered early at the median time of 2 (IQR 1-4.3) days from hospitalization and additional therapies (eg, azithromycin and hydroxychloroquine)Improved laboratory and respiratory parameters in patients following CP infusion, similar to those in controls but with lower mortality (2 vs 6 deaths)No adverse events

Liu et al 2020 [117]39 hospitalized patients (mean age 55, SD 13 years; 25 males) with severe to life-threatening COVID-19 received CP transfusion in comparison with a cohort of retrospectively matched controls (n=156)Collected by plasmapheresis from donors with antispike antibody titers ≥1:320 as measured by ELISATwo units (250 mL each unit) of ABO-type matched were infused over 1-2 hours at the median time of 4 days after admission in addition to a variety of inpatient pharmacotherapiesMore likely improvements in supplemental oxygen requirements by posttransfusion day 14, improved survival, compared to control patients, especially for nonintubated patientsNo significant transfusion-related morbidity or mortality

Perotti et al 2020 [118]46 moderate to severe COVID-19 patients (mean age 63, SD 12 years), with 19 (41%) having two or more comorbidities, in comparison with a control cohort of 23 consecutive patientsCollected using a Trima Accel blood collection device from eligible COVID-19 recovered patients with 2 consecutive negative tests for SARS‐CoV‐2, followed by pathogen reduction; neutralization titers ≥1:8024 patients received one unit of plasma, 21 received two units, and 1 patient received 3 units after having symptoms for 2 weeks, with most having been treated with antibiotics, hydroxychloroquine, and anticoagulants3 out of 46 patients (6.5%) died within 7 days (at 1, 4, and 6 days), lower than 30% in the control, and showed improved respiratory function (PaO2 /FiO2), chest radiogram, laboratory parameters (CRPr, Ferritin, LDHs, viral load), and weaning from mechanical ventilationFive serious adverse events occurred in 4 patients.

Rasheed et al 2020 [119]49 early-stage (no more than 3 days in ICU) critically ill COVID-19 patients randomized to receive CP or not (21 and 28 patients, respectively, matched in terms of age, sex, and comorbidities)Collected from healthy donors younger than 50 years who recovered from moderate COVID-19 and had a IgG index ≥1.25 as measured by ELISA400 mL of CP were transfused over 2 hours in addition to standard of care in the control groupCP-treated patients showed reduced duration of infection in about 4 days, a lower death rate (1/21 vs 8/28), and higher levels of SARS-CoV-2 IgG and IgM 3 days after CP transfusion compared to the control groupNo adverse events except that 1 patient developed mild skin redness and itching that lasted for 1 hour after CP; resolved by antihistamine injection

Roger et al 2020 [120]64 patients with symptom onset ≤10 days prior to admission and supplemental oxygen (but not invasive ventilation) within 48 h of hospitalization versus a matched control group of 177 patients for all cause in-hospital mortality and rate of hospital discharge at day 28The SARS-CoV-2 antibody content in CP was assessed retrospectively with 13% of the units below the cutoff for a positive antibody index3 of 64 patients received one and the remainder received two units of CP at a median of 7 (IQR 5-9) days after symptom onsetNo significant difference in the risk of in-hospital mortality or overall rate of hospital discharge between the two groups, except for a significantly increased hospital discharge rate among patients 65 years or older2 patients had TRALI reactions associated with the first unit of CP, and 1 had TACO approximately 3 h after transfusion of the second unit of CP

Salazar et al 2020 [121]136 severe or life-threatening COVID-19 patients treated with CP versus 215 propensity score-matched patients to assess the efficacy of CP transfusion compared to standard of careCollected from donors who had been asymptomatic for more than 14 days and had negative SARS-CoV-2 RT-PCR tests at the time of plasmapheresis; antispike IgG antibody titers ≥1:1350 as measured by ELISAThe majority of patients received one and some patients reviewed two units of CP due to worsening COVID-19 conditionsPatients treated by CP with IgG titer ≥1:1350 within 72 h of hospital admission had decreased mortality within 28 daysReported in Joyner et al 2020 [95]

Xia et al 2020 [122]1568 severe or critical COVID-19 patients, most with comorbidities, among whom 1430 patients (median age of 63 years; 50% male) only received standard treatment and 138 patients (median age of 65 years; 56% male) also received ABO-compatible CPNot reported200-1200 mL of CP were transfused at a median of 45 days of symptom onset (1 week to ≥8 weeks from symptom onset to CP therapy)Compared to that in the standard treatment group, there was a reduced mortality rate (2.2% vs 4.1%), lower admission to ICU (2.4% vs 5.1%), and improved respiratory symptoms of severe patients as evaluated by SCSStNo significant differences in cardiac, liver, and renal functions before and after CP therapy, except for a decrease in total bilirubin and 3 patients with minor allergic reactions (pruritus or erythema) during the transfusion

Xiao et al 2020 [123]18 patients with severe and critical COVID-19 divided into two groups with no significant differences in age, gender, and basic clinical data: one with CP transfusion (n=6) and the other without CP transfusion (n=12)Collected from donors between age 18-55 years who had fully recovered from COVID-19 without symptoms for 2 weeks and ≥4 weeks from symptom onset; anti–SARS-CoV-2 IgG titers >1:160200~500 mL (4~5 mL/kg body weight) of CP were transfusedNo difference between the two groups of patients in terms of ventilator and ECMO weaning time, time for viral clearance, and hospitalizationNot reported

Zeng et al 2020 [124]21 critically ill patients with COVID-19 and respiratory failure: 6 patients (median age of 61.5 years; 5 males) in the CP group versus 15 patients (median age of 73 years; 11 males) in a control group with no significant differences in demographic and clinical features200-400 mL obtained from each young adult individual who had recovered from COVID-19 for 1-2 weeks and was negative for SARS-CoV-2 RNA and IgM testing, and positive for IgG testing before donationA median volume of 300 mL CP was transfused at a median of 21.5 days after viral shedding was first detectedAll CP-treated patients tested negative for SARS-CoV-2 RNA within 3 days after infusion versus 26.7% in the control group, but 5 patients eventually died with a longer survival period, suggesting treatment should be initiated earlierNo immediate or noticeable adverse effects 

Gharbharan et al 2020 [125]86 hospitalized patients (median age of 63 years; 72% male) randomized at 1:1 for standard of care therapy with and without CPCollected from donors confirmed with an RT-PCR SARS-CoV-2 infection and were asymptomatic for at least 14 days; neutralizing antibodies titer ≥1:80 determined by a SARS-CoV-2 plaque reduction neutralization testOne unit of 300 mL ABO-compatible CP was transfused on the day of inclusion followed with the second plasma unit after 5 days for patients with persistent positive RT-PCR testsThere was no difference in day-60 mortality, hospital stay (P=.68), or day-15 disease severity (P=.58) between CP-treated patients and patients on standard care. The study was discontinued due to high neutralizing antibody titers at hospital admission in the majority of the study population.No plasma-related serious adverse events were observed

Li et al 2020 [126]103 patients (median age 70 years; 60 males, 58.3%) with severe and life-threatening COVID-19 randomized to receive CP in addition to standard treatment (n=52) or standard treatment (antiviral medications, antibacterial medications, steroids, human immunoglobulin, Chinese herbal medicines, and other medications) alone (control; n = 51)Collected based on routine plasma collection procedures via plasmapheresis from adults aged 18-55 years that were suitable for blood donation, initially diagnosed with COVID-19 but with 2 negative PCR results from nasopharyngeal swabs (at least 24 h apart) prior to hospital discharge, discharged for ≥2 weeks from the hospital, and had no persisting COVID-19 symptoms. CP S-RBD–specific IgG titer ≥1:640 correlating to serum neutralization titre of 1:80ABO-compatible CP was transfused at approximately 4-13 mL/kg of recipient body weight and at approximately 10 mL for the first 15 minutes, which was then increased to approximately 100 mL per hour with close monitoringMore clinical improvement occurred within 28 days in the CP group than in the control group among those with severe disease (91.3% vs 68.2%; P=.03) but not for those with life-threatening disease (20.7% vs 24.1%; P=.83). There was a higher negative conversion rate of viral PCR at 72 hours in the CP group than in the control group (87.2% vs 37.5%; P<.001).2 patients in the CP group experienced adverse events within hours after transfusion that improved with supportive care

aCP: convalescent plasma.

bPCR: polymerase chain reaction.

cICU: intensive care unit.

dECMO: extracorporeal membranous oxygenation.

eELISA: enzyme-linked immunosorbent assay.

fCT: computed tomography.

gASCT: autologous stem cell transplantation.

hRT-PCR: real-time polymerase chain reaction.

iS-RBD: spike protein receptor-binding domain.

jXLA: X-linked agammagloblulinemia.

kqPCR: quantitative polymerase chain reaction.

lARDS: acute respiratory distress syndrome.

mFDA: Food and Drug Administration.

nTRALI: transfusion-related acute lung injury.

oSAE: serious adverse event.

pTACO: transfusion-associated circulatory overload.

qSOT: solid organ transplant.

rCRP: C-reactive protein.

sLDH: lactate dehydrogenase.

tSCSS: six-category scale score.

uRCT: randomized controlled trial.

Patient Demographics

A total of 36,379 patients, with most patients (n=35,322) from a single study [97], have been treated with CP in all clinical studies included in this review. There is a patient heterogeneity across the clinical studies in terms of age (ranging from infant [81] and 6 [70] to 100 years [79]), gender, and different underlying diseases, in particular hypertension and diabetes [114,122,124,294]. Some case studies investigated CP therapy for COVID-19 in patients who were immune compromised or deficient [56,80,94,100,103,125].

A few studies reported the antibody titers of patients before CP transfusion, which varied from undetectable IgG RBD antibody levels (<1:50 serum dilution) to extremely high levels (1:25,600) [88]. Studies suggested that patients with low antibody levels may benefit more from CP therapy [88,125].

Donor Selection and CP Antibody Titer

Most individuals with previous laboratory-diagnosed SARS-CoV-2 infection developed measurable antibody responses and neutralizing antibodies. There is evidence for a significant decline in neutralizing antibody levels over time [280].

Studies suggest that the efficacy of CP depends on the antibody levels of the donor plasma and CP, with high antibody levels possibly conferring immediate immunity to recipients [122]. One key factor associated with CP therapy is the neutralizing antibody titer, and when the infused plasma has a high antibody titer, it may be of the greatest benefit [88,97,99,113]. Hence, it may be a prerequisite to find eligible donors who have high levels of neutralizing antibody.

Prior smaller studies have reported a variety of titer cut-offs [105,115]. The FDA has recommended that CP with a virus neutralizing antibody titer of ≥1:160 be used for therapeutic transfusion [295]. Recently, the FDA has updated its EUA to limit the authorization to the use of high titer CP for the treatment of hospitalized patients with COVID-19 early in the disease course and to those hospitalized who have impaired humoral immunity and cannot produce an adequate antibody response, and include additional tests to be used in the manufacture of COVID-19 CP [296]. Studies have reported the levels of CP antibody titer, ranging from no minimum neutralizing antibody titer level [96] to 1:640 [115], and an even wider range of RBD-specific IgG titer, from <1:160 to >1:6000 within the same study [88].

There was substantial heterogeneity in the antibody response among potential CP donors, but sex, age, and hospitalization emerged as factors that can be used to identify individuals with a high likelihood of having strong antiviral antibody levels [297]. In vitro testing of CP showed a tendency of higher neutralizing antibody titers from donors with increased disease severity, of advanced age, and of male sex; however, the clinical relevance of this difference needs to be investigated [109,270,276,277,283,284]. Moreover, pooling CP samples from many donors may prove more effective for increasing and standardizing anti–SARS-CoV-2 neutralizing antibody titers [19].

In addition, CP collection efforts should be organized around the temporal dynamics of the immune response to viral clearance and a rise in neutralizing antibody titer, with a recommended window for plasma collection beginning at 4 weeks after the resolution of symptoms and narrowing rapidly by 12 weeks [165].

Timing and Dose

One key factor associated with CP efficacy is the optimal treatment time point [115]. The phase of the disease that this treatment modality may be most beneficial is still a matter of some debate, with early versus intermediate-late stages of the cytokine storm reaction being associated with acute respiratory distress syndrome or other severe disease complications [298].

There was no therapeutic effect from CP treatment on severely or critically ill patients with COVID-19 more than 2 weeks after the onset of disease as reported by Liu et al [117]. However, CP therapy has been limited to patients with severe or critical COVID-19. The majority of patients were severe or critically ill with COVID-19, with only a few mild cases [79,90,109].

Similar to most viral illnesses, viremia in COVID-19 peaks in the first week of infection, and the primary immune response develops by days 10-14, which is followed by virus clearance. Therefore, transfusion of CP at the early stage of disease theoretically should be more effective [114,121,124]. CP appears to be of greater clinical benefit when administered early in the course of disease than delaying transfusion under the development of severe disease [63,108]; in principle, the course of disease does not exceed 3 weeks [67]. Studies have found that, regardless of COVID-19 severity at time of transfusion, patients that received CP earlier in their course of disease showed lower mortality, more rapid viral clearance, and shorter hospital stays [92,113].

Based on the current findings, CP treatment should be given to patients with COVID-19 at the right phase or severity of illness and at the right time point. It is known that most patients with mild COVID-19 can recover without treatment, and CP may be an improper therapy for those patients. For patients with end-stage COVID-19, treatment with CP may be unable to avert a poor outcome, as demonstrated by the current findings [108,124,294]. Therefore, CP treatment may be more beneficial if used in patients who are potentially critically ill with COVID-19 at an early stage of the disease. Thus, early recognition of patients with COVID-19 who are likely to become critically ill is important for timely treatment with CP [124].

This is in line with one of the first published RCTs of CP, in which Li and colleagues [126] found that clinical improvement was limited to those without life-threatening disease, with 91% improvement in the plasma group compared to 68% in the control arm [294]. A large multicenter study involving 35,322 patients found significant reductions in 7- and 30-day mortality with early use of CP containing high levels of SARS-CoV-2–specific IgG antibodies in a subset of patients [97].

Transfusion volume ranged from 2x50 mL [110] to 8x300 mL [112]. Total antibody dose could be calculated as the transfused volume of CP multiplied by SARS-CoV-2 neutralizing antibody titer. CP dose has also been recognized as a key characteristic that may influence CP-associated outcomes [187]. One study showed that patients transfused with 400 mL of CP tended to turn faster to viral clearance than those who received 200 mL of CP [113].


All studies that assessed adverse events have reported no or minimal adverse events [102,206]. Of major interest is one of the first large trials published so far—concerning the safety of 5000 recipients—that has identified only limited and nonunexpected transfusion complications [95]. The case series study focused on the safety of CP transfusion in COVID-19 reported that, out of 5000 patients, there were 7 transfusion-associated circulatory overload (TACO), 11 transfusion-related lung injury (TRALI), and 3 severe allergic reactions. However, the reported low incidence of serious adverse effects might be due to an extremely short time frame of observation (4 hours) [194]. The latest update of the study involving 20,000 hospitalized adults with severe or life-threatening COVID-19 further demonstrated low adverse events because of the treatment, with 36 TACO, 21 TRALI, 21 severe allergic reactions, and 38 transfusion-related thromboembolic events [96]. Consistently, other studies reported no to minimal adverse events. Half of the case reports that assessed the safety of CP did not indicate any adverse events or complications related to its use. One case series study reported 5 serious adverse events in 4 out of 46 patients [118]. The controlled studies reported 15 adverse events out of 695 patients. Overall, among a total of 20,749 patients reported with safety data, the incidence of adverse events related to CP transfusion was less than 0.8%, comparable or even lower than the incidence of adverse events related to plasma transfusions in other clinical settings [299]. There has been no evidence so far of antibody-mediated enhancement of disease in patients with COVID-19 treated with CP despite the concern that this might be a possibility in the presence of reactive but nonneutralizing antibodies against SARS-CoV-2 [170].

Although it is not yet clear whether the SARS-CoV-2 virus is transmitted by blood [300], donor selection criteria in compliance with existing policies and routine procedures should be met and pathogens reduction by solvent- or detergent–based treatments or light-based methods (especially for noncovered or detected in screening tests) should be performed in each donated plasma product as a standard for any plasma production [157,230]. Ultraviolet light and riboflavin used in the pathogen reduction process could effectively reduce SARS-CoV-2 in plasma and blood products without decreasing the quality of the blood products [301]. More studies have shown that the pathogen reduction processes did not alter neutralizing antibodies [156,272].


These were measured by SARS-CoV-2 negative PCR tests, improvements of clinical symptoms assessed by respiratory distress and fever, computed tomography, time to death, length of hospital stay, and mortality at discharge.

All case reports showed either viral load decrease/clearance or different extents of improvements of clinical symptoms with no mortality. Preliminary evidence from case reports and case series is favorable, as significant clinical and biochemical improvement and hospital discharge have been reported.

COVID-19 severity and underlying diseases affected the outcome of CP treatment. A patient with lymphoma who underwent autologous stem cell transplantation showed persistent SARS-CoV-2 viral shedding for 74 days, even with the administration of CP [77]. On the other hand, 1 study reported that 2 patients with long-term positive viral infection for 8 weeks showed substantial improvement after treatment with CP and ritonavir-boosted danoprevir [107]. Similarly, another study showed that CP therapy could rapidly reduce viral loads in more than half of 27 patients with prolonged positivity of SARS-CoV-2 for a median of 44 days after symptom onset [109]. It should be noted that most of these patients had mild COVID-19 symptoms.

Studies demonstrated that CP could effectively improve the respiratory symptoms of severe patients and help them wean from oxygen support. However, patients in extremely critical or life-threatening conditions could not benefit from CP [63,122,124,294].

The case series reported a mortality rate of 24.4% in 35,666 patients, mainly from 1 study with 35,322 patients [97]. The case-control and randomized controlled studies included a total of 2289 patients in the control group and 695 patients in the CP group, and reported a total of 219 (9.6%) and 63 (9.1%) deaths in each group, respectively. The number of patients and the mortality rates varied remarkably among these studies, from 6 [124] to 1430 patients [122] and from 0% [115] to 93.3% [124], respectively. The mortality at discharge [114] or at 28-day posttransfusion [121,294] have been reported as a primary outcome. Some studies showed improved survival for the CP group compared to its control [115,117,122], more clinical improvements [115,117], and viral clearance [115,124]. The efficacy of CP on mortality, length of hospital stay, clinical improvement, and viral clearance was further analyzed by meta-analysis of controlled studies, as presented later.

Quality Assessment of Clinical Studies

As indicated in Table 3, 52 clinical studies showed overall weak quality, 9 had moderate quality, and 1 had strong quality. Patients often had underlying medical conditions (hypertension, diabetes). Case reports and series with limited number of patients were considered weak for selection of participants (high risk of selection bias). Some studies included only males with a total of 3 patients [117] or only pediatric patients with fewer than 4 children [70,88] and therefore were judged to be weak for sample selection. Studies that targeted a specific group (eg, older populations, median age >60 years) were rated with moderate selection bias [122,124,125,294], while studies that selected patients with a broad range of ages and balanced gender and comorbidities [114,121] were ranked as strong.

Table 3. Quality assessment components and their rankings for clinical studies evaluated using the Effective Public Health Practice Project tool.
StudiesPatient selectionStudy designConfoundersBlindingData collection methodsWithdraws/ dropoutsOverall
Al Helali et al 2020 [65]WeakWeakWeakWeakWeakStrongWeak
Anderson et al 2020 [66]WeakWeakWeakWeakWeakStrongWeak
Bao et al 2020 [67]WeakWeakWeakWeakWeakStrongWeak
Cinar et al 2020 [68]WeakWeakWeakWeakModerateStrongWeak
Clark et al 2020 [69]WeakWeakWeakWeakWeakStrongWeak
Figlerowicz et al 2020 [70]WeakWeakWeakModerateModerateStrongWeak
Grisolia et al 2020 [71]WeakWeakWeakWeakModerateStrongWeak
Hahn et al 2020 [72]WeakWeakWeakWeakModerateStrongWeak
Hartman et al 2020 [73]WeakWeakModerateWeakWeakModerateWeak
Im et al 2020 [74]WeakWeakWeakWeakWeakStrongWeak
Jafari et al 2020 [75]WeakWeakWeakWeakWeakStrongWeak
Jiang et al 2020 [76]WeakWeakWeakWeakModerateStrongWeak
Karataş et al 2020 [77]WeakWeakWeakWeakWeakStrongWeak
Kong et al 2020 [79]WeakWeakWeakModerateModerateStrongWeak
Mira et al 2020 [80]WeakWeakModerateWeakModerateStrongWeak
Soleimani and Soleimani 2020 [82]WeakWeakWeakWeakWeakStrongWeak
Xu et al 2020 [83]WeakWeakWeakWeakWeakStrongWeak
Zhang et al 2020 [84]WeakWeakWeakWeakModerateStrongWeak
Ahn et al 2020 [85]WeakWeakWeakWeakStrongStrongWeak
Abdullah et al 2020 [86]WeakWeakWeakWeakWeakStrongWeak
Bradfute et al 2020 [87]ModerateWeakWeakWeakModerateStrongWeak
Diorio et al 2020 [88]WeakWeakWeakWeakStrongStrongWeak
Enzmann et al 2020 [89]WeakWeakWeakWeakWeakStrongWeak
Erkurt et al 2020 [90]ModerateWeakWeakWeakModerateStrongWeak
Fung et al 2020 [56]WeakWeakWeakWeakModerateStrongWeak
Gemici et al 2020 [91]ModerateWeakWeakWeakModerateStrongWeak
Hartman et al 2020 [63]ModerateWeakWeakWeakWeakStrongWeak
Ibrahim et al 2020 [92]ModerateWeakWeakWeakStrongStrongWeak
Bobek et al 2020 [93]WeakWeakWeakWeakModerateStrongWeak
Jin et al 2020 [94]WeakWeakWeakWeakModerateStrongWeak
Joyner et al 2020 [95]StrongWeakWeakWeakWeakStrongWeak
Joyner et al 2020 [96]StrongWeakWeakWeakModerateStrongWeak
Joyner et al 2020 [97]StrongWeakModerateWeakStrongStrongWeak
Liu et al 2020 [98]WeakWeakWeakWeakModerateStrongWeak
Maor et al 2020 [99]ModerateWeakWeakWeakStrongStrongWeak
Naeem et al 2020 [100]WeakWeakWeakWeakModerateStrongWeak
Olivares-Gazca et al 2020 [101]WeakWeakWeakWeakModerateStrongWeak
Pal et al 2020 [102]ModerateWeakWeakWeakModerateStrongWeak
Rahman et al 2020 [103]WeakWeakWeakWeakModerateStrongWeak
Salazar et al 2020 [104]WeakWeakWeakWeakStrongStrongWeak
Shen et al 2020 [105]ModerateWeakWeakWeakStrongStrongWeak
Tremblay et al 2020 [106]ModerateWeakWeakWeakModerateStrongWeak
Wang et al 2020 [108]WeakWeakWeakWeakStrongStrongWeak
Wei et al 2020 [107]WeakWeakWeakWeakWeakStrongWeak
Wu et al 2020 [109]ModerateWeakWeakWeakStrongStrongWeak
Xi et al 2020 [110]WeakWeakWeakWeakWeakModerateWeak
Ye et al 2020 [111]ModerateWeakWeakWeakStrongStrongWeak
Zhang et al 2020 [112]ModerateWeakWeakWeakModerateStrongWeak
Zeng et al 2020 [113]WeakWeakWeakWeakStrongStrongWeak
Abolghasemi et al 2020 [114]StrongModerateModerateWeakStrongStrongModerate
Duan et al 2020 [115]ModerateModerateWeakWeakStrongStrongWeak
Hegerova et al 2020 [116]ModerateModerateWeakWeakStrongStrongWeak
Liu et al 2020 [117]ModerateModerateModerateModerateStrongStrongModerate
Perotti et al 2020 [118]ModerateModerateModerateWeakStrongModerateModerate
Rasheed et al 2020 [119]ModerateStrongStrongWeakModerateStrongModerate
Roger et al 2020 [120]ModerateModerateModerateWeakStrongStrongModerate
Salazar et al 2020 [121]StrongModerateModerateWeakStrongStrongModerate
Xia et al 2020 [122]ModerateModerateModerateWeakModerateStrongModerate
Xiao et al 2020 [123]WeakModerateModerateWeakModerateStrongWeak
Zeng et al 2020 [124]ModerateModerateModerateWeakModerateStrongModerate
Gharbharan et al 2020 [125]ModerateStrongStrongWeakStrongStrongModerate
Li et al 2020 [126]ModerateStrongStrongModerateStrongStrongStrong

With respect to the study design, case reports and series were considered to be weak; case-control studies and RCTs were determined to be moderate and strong, respectively. The confounders for case reports and series studies were ranked weak given the uncontrolled nature of these studies involving other therapeutic treatments and supportive care and the use of other treatment regimens, including antiviral medications along with CP transfusion. Two different analytical methods were used to control for confounding in 1 case series study [97] subsequently determined to be of moderate risk for confounders. This component was ranked to be strong for RCTs and moderate for case-control studies, except for 1 study by Duan et al [115] given the uncertain characteristics of participants selected into the intervention group and the use of a historical control group.

As CP treatment was not blinded to either outcome assessors or study patients in most studies, the blinding component was judged to be weak except for the RCT by Li et al [126], where the evaluation of clinical outcomes was performed by an investigator who was blind to the treatment.

If there was no detailed CP therapy in terms of CP collection, neutralizing antibody or anti–SARS-CoV-2 IgG titers, timing and dose of the treatment, and valid measures of clinical outcomes, the data collection methods of the study were deemed to be weak. Some case reports did not provide any information for CP donators, antibody titers, and adverse events [66,67].

There were no dropouts in the case reports and case series. One case series study where all patients were followed up for only 7 days [118] was ranked as moderate. In the RCT reported by Gharbharan et al [125], all 86 patients had been followed for at least 15 days after inclusion, and 75 and 32 patients for at least 30 and 60 days, respectively.

Both RCTs were terminated prematurely due to the concerns over the potential benefit of CP in the study population with high neutralizing antibody titers (≥1:160) at baseline [125] and the lack of patients with COVID-19 to reach the planned recruitment target of 200 patients [294], resulting in an underpowered study sample size.


Figures 2-5 summarize the statistical analyses of pooled results from the controlled clinical studies addressing the efficacy of CP treatment for COVID-19. We found 13 controlled articles (2 RCTs and 11 cohort studies) assessing mortality, with a total of 695 and 2289 patients in the CP and control groups, respectively. CP reduced the mortality by half in COVID-19 (OR 0.48, 95% CI 0.34-0.67; I2=0), as demonstrated in the forest plot (Figure 2).

However, fewer studies were available to assess the effects of CP treatment on the length of hospital stay, clinical improvement, and viral clearance. We identified only 6 studies (1 RCT and 5 cohort studies) reporting the length of hospital stay, with a total of 366 and 1735 patients in the CP and control groups, respectively (Figure 3). These studies had significant heterogeneity (P<.001; I2=95%) and, when combined, did not show any effects of CP treatment on the length of hospital stay (mean difference 0.84, 95% CI –3.35 to 5.02 days).

Similarly, 4 studies (2 RCTs and 2 cohort studies) assessed the clinical improvement with the number of patients in both CP and control groups. As depicted in Figure 4, a larger portion of the patients in the CP group showed improved clinical status compared to that in the control, but the difference was not statistically significant (OR 1.54, 95% CI 0.79-3.01; I2=43%).

Based on the 3 studies (1 RCT and 2 cohort studies) with a total of 63 and 65 patients in the CP and control groups, respectively, we found that the use of CP increased the viral clearance significantly (OR 26.21, 95% CI 4.36-157.66; I2=43%) as shown in Figure 5.

Figure 2. Efficacy of CP treatment on mortality in COVID-19 patients. Data from 13 controlled clinical trials were pooled using an inverse variance method and analyzed using a random-effects model. Odds ratios and 95% CIs were used as statistical measures for mortality as a dichotomous outcome. CP: convalescent plasma.
View this figure
Figure 3. Efficacy of CP treatment on length of hospital stay in COVID-19 patients. Data from 6 controlled clinical trials were pooled using an inverse variance method and analyzed using a random-effects model. Means and SDs were the statistical measures used to describe the length of hospital stay. CP: convalescent plasma.
View this figure
Figure 4. Efficacy of CP treatment on clinical improvement in COVID-19 patients. Data from 4 controlled clinical trials were pooled using an inverse variance method and analyzed using a random-effects model. Odds ratios and 95% CIs were used as statistical measures for clinical improvement as a dichotomous outcome. CP: convalescent plasma.
View this figure
Figure 5. Efficacy of CP treatment on viral clearance in COVID-19 patients. Data from 3 controlled clinical trials were pooled using an inverse variance method and analyzed using a random-effects model. Odds ratios and 95% CIs were used as statistical measures for viral clearance as a dichotomous outcome. CP: convalescent plasma.
View this figure

Except for the high heterogeneity among the studies on assessing the length of hospital stay (I2=0.98; P<.001), the heterogeneity among the studies assessing the clinical improvement and viral clearance was mild (I2=43%, P=.16 and I2=38%, P=.20, respectively). Furthermore, since the included studies on the efficacy of CP treatment for mortality are homogenous (I2=0; P=.99), the overall effect on the mortality from the meta-analysis seems to be conclusive.

Mechanisms of Action

The biological basis for efficacy of CP entails the transfer of specific antiviral immunoglobulins (antibodies) and other bioactive substances in the plasma of patients in the convalescent phase of COVID-19 infection [233,302]. In theory, administration of CP containing high levels of polyclonal neutralizing antibodies (comprised mainly of IgG, with smaller amounts of IgM, IgA) can confer immediate pathogen-specific protection by inhibiting viral infection in a susceptible person [303]. However, findings suggest considerable variation in antibody titers and the duration of protective anti–SARS-CoV-2 IgG and IgM immunity observed in recovered CP donors [304,305]. A recent population-based study of humoral immune responses to SARS-CoV-2 demonstrated that >90% of people who recovered from COVID-19 were seropositive on virus-specific pan-immunoglobulin assays by day 25, and hospitalized patients seroconverted more frequently than nonhospitalized people. Furthermore, anti–SARS-CoV-2 antibody titers remained stable in recovered patients for the next 2 months, suggesting a durable immunoglobulin response [306]. Aside from CP, pooled human immunoglobulins may also be prepared from plasma as a concentrated antibody-containing solution to be administered as intravenous, subcutaneous, or intramuscular immunoglobulin. These pooled plasma-derived immunoglobulin products benefit from the polyclonal response of each individual donor and from the interindividual variability in such responses [307]. In addition, purified, high-titer hyperimmune immunoglobulin formulations can be obtained from vaccinated or convalescing donors, which have known levels of plasma-derived neutralizing antibodies that may prove valuable against COVID-19 [33,207,225].

Although not fully elucidated, the protective mechanisms of CP are based on direct and indirect antiviral activities, including antibody neutralization of viral infectivity [233,307]. In the case of SARS-CoV-2 pathogenesis, the viral spike glycoprotein is critical to the dissemination and pathogenesis of the virus [308]. The spike protein mediates binding of SARS-CoV-2 to host cell ACE-2 surface receptors, thereby acting as the first step in cellular entry and infection. Several lines of evidence from studies of SARS-CoV and CoV-2 show that infected hosts produce neutralizing antibodies directed against the RBD of the homotrimeric spike protein and can block infection by preventing viral entry and subsequent replication [309]. Other beneficial immune effects of CP are thought to include enhanced antibody-dependent cellular cytotoxicity, complement activation, and phagocytosis, along with restoration of the vascular endothelial glycocalyx [34,200]. Moreover, a majority of convalescent patients display robust antiviral SARS-CoV-2–specific T cell responses, with enhanced in vivo priming and expansion of CD8+ cytotoxic T cells and a higher frequency of CD4+ memory T cells in those who recovered from severe COVID-19, which may provide long-term antiviral protection even if antibodies wane [310]. Therefore, T cells could help to control SARS-CoV-2 infection and serve as correlates of protective antiviral immunity [311].

As new strains of SARS-CoV-2 with several dominant mutations in the spike protein have been identified recently, crucial questions associated with the possible reinfection of recovered patients and the efficiencies of vaccines designed based on early epidemic strains have arisen [22]. Recent findings show that sera collected from convalescent COVID-19 patients in early 2020 vaccinated with RBD-based vaccines efficiently neutralize viral variants of D614G and B.1.1.7 but weakly neutralize those of 501Y.V2, suggesting a warning to recovered patients and developed vaccines [312]. These results show that, as mutations accumulate in the RBD, spike proteins may acquire an antigenic shift that enable SARS-CoV-2 variants with loss-of-neutralization potency in vitro against emerging variants and eventually resist the current vaccines. Therefore, intensive monitoring of virus mutations and timely adjustments to the spike sequences of designed vaccines and updated antibody cocktail therapies, targeting highly conserved regions, are required to control the viral pandemic [313].

Main Findings

This systematic review summarizes a variety of evidence on the use of CP for treatment of COVID-19. Though the focus of this review was to identify and assess the quality of clinical studies reporting CP treatment for COVID-19, the broad search strategy identified a large number of studies related to various aspects of CP use, highlighting substantial research in this field. The data on this topic is being rapidly generated and reported. Most are commentary and review articles and protocol or guidance descriptions on the theme of CP treatments for COVID-19. The main findings according to each group of articles dealing with COVID-19 CP were:

  1. Clinical studies: Overall, there were significant variations among the studies regarding the study design and population, the timing of initiation of CP transfusion, dosage and neutralizing antibody titer, and concomitant therapy. The quality of the current evidence on the use of CP for COVID-19 was low. However, there is a widespread belief that CP should be used given that no other efficacious treatment is currently available.
  2. Commentary articles: This category mainly consisted of commentary and letter to the editor in addition to a few editorials and perspectives that collectively supported the use of CP for COVID-19 and suggested further clinical trials.
  3. Review: The volume and the pace of the clinical trials launched to evaluate the safety and efficacy of CP against COVID-19 reflects the need for high-quality evidence for the therapy to be practiced by clinicians.
  4. Protocol and guideline: This category of literature showed the importance for establishment of a CP production and storage transfusion program in a public health care network and a decision-making framework; the requirements applicable to plasma donors; and the standards for preparation, qualification, storage, distribution, and control of product use.
  5. In vitro testing of CP: A variety of tests have been developed to measure the levels of CP antibodies. Generally, two methods have been most used to determine antibody titers of CP: ELISA for IgG and IgM, and neutralization assay for neutralizing antibodies. ELISA-based antibody titers can correlate well with neutralizing titers.

Our meta-analysis of controlled studies showed significant reduction in mortality by CP therapy in comparison to controls. Similar meta-analysis of the efficacy of CP therapy on different types of infectious disease found a 44% reduction in the mortality of patients with COVID-19 [208]; a 25% reduction in other severe acute respiratory infections [33]; and a 32% reduction in SARS-CoV infection, severe influenza, and Ebola infection [209]. In contrast, the meta-analysis from 4 RCTs on CP treatment for influenza infection (n=572 patients) showed no convincing effects on deaths [206]. Another recent systematic review of 1 RCT and 3 controlled nonrandomized studies of CP therapy in patients with COVID-19 reported a potential reduction in mortality, time to death, and improvement of clinical symptoms but was unable to provide any opinion regarding the efficacy of CP treatment for COVID-19 due to paucity in quantitative synthesis [207].

Our meta-analysis showed no effect of CP on the length of hospital stay (mean difference), which is consistent with another meta-analysis of 3 RCTs for the effect of CP on the length of hospitalization in other severe respiratory viral infections, as reported by Devasenapathy et al [206]. Other systematic reviewers reported mixed results of both reduced length of hospital stay and no effects on the length of hospitalization in SARS-CoV infection, severe influenza, and Ebola infection [209], suggesting that the effectiveness of CP in reducing hospital length of stay might be dependent on early administration of the therapy, and its use as prophylaxis is more likely to be beneficial than treating severe disease [33]. However, the optimal timing and dosage of CP therapy remains to be defined.

The insignificant effect of CP on the improvements of clinical COVID-19 symptoms is comparable to another systematic review and meta-analysis of 5 studies with a total of 259 patients with COVID-19, showing more clinically improved patients treated with CP than no CP treatment but was not statistically significant (OR 2.06, 95% CI 0.8-4.9; I2=44%) [208]. In contrast, the meta-analysis of 9 controlled and uncontrolled studies showed improved clinical status of patients with COVID-19 when compared to baseline (ROM 0.53, 95% CI 0.36-0.79; P<.01; n=149) [147].

The significant increase in the viral clearance is also consistent with the other meta-analysis of 2 studies with a total of 144 patients, suggesting that the use of CP helps in viral clearance significantly [208], and with the meta-analysis of 9 controlled and uncontrolled studies showing reduced viral loads [147].

Various tools have been developed for quality assessment involving slightly different components and ranking criteria [314]. We used the EPHPP tool as it can be used for all types of clinical studies. This is a generic tool used to evaluate a variety of intervention study designs such as RCTs, before-and-after, and case-control studies [62]. A study has shown differences in quality assessment for RCTs between the EPHPP and the Cochrane Collaboration Risk of Bias tool [315]. Overall, clinical studies and systematic reviews have confirmed that CP caused few or no serious adverse events with low-quality evidence.

Consistent with other reviews [207,208], our quality appraisal showed that the present studies on the efficacy of CP are generally of low quality, although there are certain agreements and discrepancies between our assessment and others on the overall quality of case and randomized controlled studies on the use of CP for COVID-19, as different assessment tools have been used. Only 1 high-quality (low risk of bias in the underlying study results) RCT by Li et al [126] was identified in our assessment using the EPHPP tool, which is in agreement with the assessment in the systematic review by Sarkar et al [208], but was rated to be unclear in another systematic review by Piechotta et al [207], even though both reviews used the same Cochrane risk-of-bias tool (RoB 2.0) for the RCT.

The overall quality of the case-control studies in our assessment lies in between the risk of bias assessed by other two systematic reviews conducted by Piechotta et al [207] and Sarkar et al [208]. Specifically, the study by Duan et al [115] was considered weak in our quality assessment but was critical as assessed by Piechotta et al [207] and moderate risk of bias by Sarkar et al [208] in their reviews. The case-control study reported by Liu et al [117] was of moderate quality in our assessment but was critical and had a low risk of bias as assessed by Piechotta et al [207] and Sarkar et al [208], respectively, using the same Risk of Bias in Non-randomized Studies–of Interventions. The case-control study reported by Zeng et al [124] was moderate in our assessment, agreeing with the assessment in the systematic review by Sarkar et al [208], but was rated to be a critical risk of bias in the systematic review by Piechotta et al [207]. In addition to controlled and randomized studies, EPHPP could be used to assess the quality of case reports and series studies [62]. The overall quality of all case reports and series were weak based on our assessment.

Considering the promising evidence from existing clinical data, there is a clear need for RCTs on large patient numbers to evaluate the efficacy of CP therapy. Apart from sample size and the noncomparative, nonrandomized study design, numerous limitations hamper the interpretation of the aforementioned studies, such as the superimposition of effects mediated by other antiviral treatments, antibiotics, and glucocorticoids administered concomitantly with CP. As a whole, these studies indicate that patients receiving transfusions earlier than 14 days post infection may benefit from CP treatment [228,230].


There are 2 systematic reviews and meta-analysis to appraise the literature on CP therapy for patients with COVID-19. However, this review covers the latest literature as of the date of our manuscript submission and provides insights about various aspects for the subject on the use of CP for COVID-19 that needs further investigation. The primary limitation of this review is that most data identified are nonrandomized (only 2 out of 64 clinical studies were randomized, with only 1 being of high quality), and therefore, confounding is highly inevitable. Furthermore, study populations, interventions, and measured outcomes have important clinical and methodological heterogeneity, which reflects an overall low to moderate quality of evidence identified by the appropriate quality assessment tool.

Publication bias may be another potential limitation given that the majority of early clinical studies on COVID-19 lacked original data, and those that did were rushed and did not include the appropriate measures to reduce bias [316]. Among the 243 papers included in this review, 32.5% (n=79) were commentaries, 18.9% (n=46) were reviews, and 7.8% (n=19) were protocols that did not contain any new data. We then evaluated the quality of the original clinical studies using the validated tool and found that more than 80% (52/64) were at risk of bias, mainly because of few participants, unrepresentative patient selection, poor study design, no control of confounders, and no blinding.

Future Directions

We summarized various aspects of the evidence on the use of CP in patients with COVID-19. However, important gaps in knowledge remain. Notably, the following areas require further investigation.

Well-designed prospective observational studies, preferentially RCTs, with well-defined characteristics for both CP donors and recipients are warranted to answer questions concerning the effects on mortality or other important clinical outcomes such as improvement in symptoms and respiratory status. The placebo or control should include standard-of-care or normal fresh frozen plasma. The plasma exchange has shown therapeutic effects for severe COVID-19 acute respiratory distress syndrome with multiple organ failure [317].

In vitro testing showed variable or diverse neutralizing antibody titers among individual donors, suggesting that an adequate pooling strategy of plasma units from different donors could reduce the variability of neutralizing antibody titers of CP and compensate deviations of individual antibody titers [289]. Clinical studies on the safety and efficacy of pooled CP should be conducted.

The COVID-19 pandemic has substantially reduced the national ability to provide blood products for medical care in an emergency [318], which further highlights the need to secure a stockpile of blood products with a long shelf life (eg, freeze-dried plasma) to be self-sufficient in a national crisis. Current CP protocols specify that, once thawed, CP may be stored for up to 5 days at 4 °C, similar to that of fresh frozen plasma. A recent study has demonstrated long-term stability of anti–SARS-CoV-2 spike antibodies in donor CP for 42 days when stored under refrigerated conditions [291]. There will be a need to stockpile freeze-dried CP for future waves of the pandemic for several years. Additionally, global concern over the potential for future waves of infection to occur before effective vaccines or drug therapies are available has many looking at other biological sources for large-scale production of neutralizing SARS-CoV-2 antibodies. Taking this into consideration, we are developing COVID-19 convalescent freeze-dried plasma. As this is a pooled plasma product of 10 donors, we also hypothesize that convalescent freeze-dried plasma will have higher anti–SARS-CoV-2 neutralizing antibody titers and activity than single donor CP. As well, this product may be administered in a hypertonic solution for those patients who cannot tolerate large volume CP transfusions.


There is still limited evidence but accumulating interest in CP treatment for COVID-19. The theoretical reasons for the likely efficacy of passive immunization, the urgent need felt by clinicians worldwide for effective treatment options for COVID-19, and the promising results offered mainly by retrospective clinical studies must be balanced against the lack of efficacy in the RCTs of CP and hyperimmune globulin therapy in severe influenza and COVID-19.

CP may be of greatest benefit for patients who are early in their illness and have not yet generated endogenous antibodies, and when the infused CP has a high antibody titer. Recurring observations suggested that treatment with CP within 4-5 days of symptom onset might be more effective than later treatment.

Our systematic review and analysis emphasizes the low quality of clinical studies. These studies could provide important lessons that should inform the planning of adequately powered and properly designed RCTs to evaluate the promise of CP therapy for patients with COVID-19.

Future research is necessary to fill the obvious knowledge gaps regarding CP treatment for patients with COVID-19. In brief, we offered recommendations around the need for a large-scale properly designed RCT, the potential prophylactic use of CP, selection criteria for both CP donors and recipients, development of antibodies with higher potency than CP, and freeze-dried CP as a long-term strategy against the pandemic.


We would like to thank Defence Research and Development Canada for funding support.

Conflicts of Interest

None declared.

Multimedia Appendix 1

Supplemental Table 1.

DOCX File , 486 KB

  1. Zhu N, Zhang D, Wang W, Li X, Yang B, Song J, China Novel Coronavirus Investigating and Research Team. A novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med 2020 Feb 20;382(8):727-733 [FREE Full text] [CrossRef] [Medline]
  2. Yesudhas D, Srivastava A, Gromiha MM. COVID-19 outbreak: history, mechanism, transmission, structural studies and therapeutics. Infection 2020 Sep 04:199-213 [FREE Full text] [CrossRef] [Medline]
  3. Perlman S. Another decade, another coronavirus. N Engl J Med 2020 Feb 20;382(8):760-762 [FREE Full text] [CrossRef] [Medline]
  4. Struyf T, Deeks J, Dinnes J, Takwoingi Y, Davenport C, Leeflang M, Cochrane COVID-19 Diagnostic Test Accuracy Group. Signs and symptoms to determine if a patient presenting in primary care or hospital outpatient settings has COVID-19 disease. Cochrane Database Syst Rev 2020 Jul 07;7:CD013665 [FREE Full text] [CrossRef] [Medline]
  5. Hasani H, Mardi S, Shakerian S, Taherzadeh-Ghahfarokhi N, Mardi P. The novel coronavirus disease (COVID-19): a PRISMA systematic review and meta-analysis of clinical and paraclinical characteristics. Biomed Res Int 2020;2020:3149020. [CrossRef] [Medline]
  6. Rajgor DD, Lee MH, Archuleta S, Bagdasarian N, Quek SC. The many estimates of the COVID-19 case fatality rate. Lancet Infect Dis 2020 Jul;20(7):776-777 [FREE Full text] [CrossRef] [Medline]
  7. Del Rio C, Collins LF, Malani P. Long-term health consequences of COVID-19. JAMA 2020 Oct 05:1723-1724. [CrossRef] [Medline]
  8. Chattu VK, Adisesh A, Yaya S. Canada's role in strengthening global health security during the COVID-19 pandemic. Glob Health Res Policy 2020;5:16 [FREE Full text] [CrossRef] [Medline]
  9. Gebru A, Birhanu T, Wendimu E, Ayalew A, Mulat S, Abasimel H, et al. Global burden of COVID-19: situational analyis and review. Hum Antibodies 2020 Jul 24:1. [CrossRef] [Medline]
  10. Rizwan K, Rasheed T, Khan SA, Bilal M, Mahmood T. Current perspective on diagnosis, epidemiological assessment, prevention strategies, and potential therapeutic interventions for severe acute respiratory infections caused by 2019 novel coronavirus (SARS-CoV-2). Hum Vaccin Immunother 2020 Dec 01;16(12):3001-3010. [CrossRef] [Medline]
  11. Kaddoura M, AlIbrahim M, Hijazi G, Soudani N, Audi A, Alkalamouni H, et al. COVID-19 therapeutic options under investigation. Front Pharmacol 2020;11:1196. [CrossRef] [Medline]
  12. Koyama T, Weeraratne D, Snowdon J, Parida L. Emergence of drift variants that may affect COVID-19 vaccine development and antibody treatment. Pathogens 2020 Apr 26;9(5):324 [FREE Full text] [CrossRef] [Medline]
  13. Liu W, Zhou P, Chen K, Ye Z, Liu F, Li X, et al. Efficacy and safety of antiviral treatment for COVID-19 from evidence in studies of SARS-CoV-2 and other acute viral infections: a systematic review and meta-analysis. CMAJ 2020 Jul 06;192(27):E734-E744 [FREE Full text] [CrossRef] [Medline]
  14. Meo SA, Zaidi SZA, Shang T, Zhang JY, Al-Khlaiwi T, Bukhari IA, et al. Biological, molecular and pharmacological characteristics of chloroquine, hydroxychloroquine, convalescent plasma, and remdesivir for COVID-19 pandemic: A comparative analysis. J King Saud Univ Sci 2020 Oct;32(7):3159-3166 [FREE Full text] [CrossRef] [Medline]
  15. WHO Rapid Evidence Appraisal for COVID-19 Therapies (REACT) Working Group, Sterne JAC, Murthy S, Diaz JV, Slutsky AS, Villar J, et al. Association between administration of systemic corticosteroids and mortality among critically ill patients with COVID-19: a meta-analysis. JAMA 2020 Oct 06;324(13):1330-1341 [FREE Full text] [CrossRef] [Medline]
  16. Yang Z, Liu J, Zhou Y, Zhao X, Zhao Q, Liu J. The effect of corticosteroid treatment on patients with coronavirus infection: a systematic review and meta-analysis. J Infect 2020 Jul;81(1):e13-e20 [FREE Full text] [CrossRef] [Medline]
  17. Mellet J, Pepper MS. A COVID-19 vaccine: big strides come with big challenges. Vaccines (Basel) 2021 Jan 11;9(1):39 [FREE Full text] [CrossRef] [Medline]
  18. Singh R, Kang A, Luo X, Jeyanathan M, Gillgrass A, Afkhami S, et al. COVID-19: current knowledge in clinical features, immunological responses, and vaccine development. FASEB J 2021 Mar;35(3):e21409 [FREE Full text] [CrossRef] [Medline]
  19. Machhi J, Herskovitz J, Senan AM, Dutta D, Nath B, Oleynikov MD, et al. The natural history, pathobiology, and clinical manifestations of SARS-CoV-2 infections. J Neuroimmune Pharmacol 2020 Sep;15(3):359-386 [FREE Full text] [CrossRef] [Medline]
  20. Wherry EJ, Jaffee EM, Warren N, D'Souza G, Ribas A, AACR COVID-19 and Cancer Task Force. How did we get a COVID-19 vaccine in less than 1 year? Clin Cancer Res 2021 Feb 04:1. [CrossRef] [Medline]
  21. Forni G, Mantovani A, COVID-19 Commission of Accademia Nazionale dei Lincei, Rome. COVID-19 vaccines: where we stand and challenges ahead. Cell Death Differ 2021 Feb;28(2):626-639 [FREE Full text] [CrossRef] [Medline]
  22. Mascola JR, Graham BS, Fauci AS. SARS-CoV-2 viral variants-tackling a moving target. JAMA 2021 Feb 11:1. [CrossRef] [Medline]
  23. Su Z, Wen J, McDonnell D, Goh E, Li X, Šegalo S, et al. Vaccines are not yet a silver bullet: the imperative of continued communication about the importance of COVID-19 safety measures. Brain Behav Immun Health 2021 Mar;12:100204 [FREE Full text] [CrossRef] [Medline]
  24. Su S, Wang Q, Jiang S. Facing the challenge of viral mutations in the age of pandemic: developing highly potent, broad-spectrum, and safe COVID-19 vaccines and therapeutics. Clin Transl Med 2021 Jan;11(1):e284. [CrossRef] [Medline]
  25. Bajwah S, Wilcock A, Towers R, Costantini M, Bausewein C, Simon ST, et al. Managing the supportive care needs of those affected by COVID-19. Eur Respir J 2020 Apr;55(4):2000815. [CrossRef] [Medline]
  26. Pavia CG, Wormser GP. Passive immunization and its rebirth in the era of the COVID-19 pandemic. Int J Antimicrob Agents 2021 Mar;57(3):106275 [FREE Full text] [CrossRef] [Medline]
  27. Focosi D, Anderson AO, Tang JW, Tuccori M. Convalescent plasma therapy for COVID-19: state of the art. Clin Microbiol Rev 2020 Sep 16;33(4):e00072-e00020 [FREE Full text] [CrossRef] [Medline]
  28. Chen L, Xiong J, Bao L, Shi Y. Convalescent plasma as a potential therapy for COVID-19. Lancet Infect Dis 2020 Apr;20(4):398-400 [FREE Full text] [CrossRef] [Medline]
  29. Morabito CJ, Gangadharan B. Active therapy with passive immunotherapy may be effective in the fight against COVID-19. Clin Transl Sci 2020 Sep;13(5):835-837 [FREE Full text] [CrossRef] [Medline]
  30. AminJafari AS, Ghasemi S. The possible of immunotherapy for COVID-19: a systematic review. Int Immunopharmacol 2020 Jun;83:106455 [FREE Full text] [CrossRef] [Medline]
  31. Marson P, Cozza A, De Silvestro G. The true historical origin of convalescent plasma therapy. Transfus Apher Sci 2020 Oct;59(5):102847 [FREE Full text] [CrossRef] [Medline]
  32. Mansourabadi AH, Sadeghalvad M, Mohammadi-Motlagh H, Rezaei N. The immune system as a target for therapy of SARS-CoV-2: a systematic review of the current immunotherapies for COVID-19. Life Sci 2020 Oct 01;258:118185 [FREE Full text] [CrossRef] [Medline]
  33. Mair-Jenkins J, Saavedra-Campos M, Baillie JK, Cleary P, Khaw F, Lim WS, Convalescent Plasma Study Group. The effectiveness of convalescent plasma and hyperimmune immunoglobulin for the treatment of severe acute respiratory infections of viral etiology: a systematic review and exploratory meta-analysis. J Infect Dis 2015 Jan 01;211(1):80-90 [FREE Full text] [CrossRef] [Medline]
  34. Casadevall AL, Pirofski LA. The convalescent sera option for containing COVID-19. J Clin Invest 2020 Apr 01;130(4):1545-1548. [CrossRef] [Medline]
  35. Marano G, Vaglio S, Pupella S, Facco G, Catalano L, Liumbruno GM, et al. Convalescent plasma: new evidence for an old therapeutic tool? Blood Transfus 2016 Mar;14(2):152-157. [CrossRef] [Medline]
  36. Montelongo-Jauregui D, Vila T, Sultan AS, Jabra-Rizk MA. Convalescent serum therapy for COVID-19: a 19th century remedy for a 21st century disease. PLoS Pathog 2020 Aug;16(8):e1008735 [FREE Full text] [CrossRef] [Medline]
  37. Luke TC, Kilbane EM, Jackson JL, Hoffman SL. Meta-analysis: convalescent blood products for Spanish influenza pneumonia: a future H5N1 treatment? Ann Intern Med 2006 Oct 17;145(8):599-609 [FREE Full text] [CrossRef] [Medline]
  38. Watson J, Pati S, Schreiber M. Plasma transfusion: history, current realities, and novel improvements. Shock 2016 Nov;46(5):468-479. [CrossRef] [Medline]
  39. Hung IF, To KK, Lee C, Lee K, Chan K, Yan W, et al. Convalescent plasma treatment reduced mortality in patients with severe pandemic influenza A (H1N1) 2009 virus infection. Clin Infect Dis 2011 Feb 15;52(4):447-456 [FREE Full text] [CrossRef] [Medline]
  40. Keller MA, Stiehm ER. Passive immunity in prevention and treatment of infectious diseases. Clin Microbiol Rev 2000 Oct;13(4):602-614 [FREE Full text] [CrossRef] [Medline]
  41. Pérez-Cameo C, Marín-Lahoz J. Serosurveys and convalescent plasma in COVID-19. EClinicalMedicine 2020 Jun;23:100370 [FREE Full text] [CrossRef] [Medline]
  42. Lung T, Kazatchkine MD, Risch L, Risch M, Nydegger UE. A consideration of convalescent plasma and plasma derivatives in the care of severely-ill patients with COVID-19. Transfus Apher Sci 2020 Oct;59(5):102936 [FREE Full text] [CrossRef] [Medline]
  43. Sheridan C. Convalescent serum lines up as first-choice treatment for coronavirus. Nat Biotechnol 2020 Jun;38(6):655-658. [CrossRef] [Medline]
  44. Tanne JH. Covid-19: FDA approves use of convalescent plasma to treat critically ill patients. BMJ 2020 Mar 26;368:m1256. [CrossRef] [Medline]
  45. Emergency use authorization of medical products and related authorities: guidance for industry and other stakeholders. US Food and Drug Administration.   URL: [accessed 2020-09-27]
  46. Hossen MS, Barek MA, Jahan N, Safiqul Islam M. A review on current repurposing drugs for the treatment of COVID-19: reality and challenges. SN Compr Clin Med 2020 Aug 31:1-13 [FREE Full text] [CrossRef] [Medline]
  47. Rubin R. Testing an old therapy against a new disease: convalescent plasma for COVID-19. JAMA 2020 Jun 02;323(21):2114-2117. [CrossRef] [Medline]
  48. Weinreich DM, Sivapalasingam S, Norton T, Ali S, Gao H, Bhore R, Trial Investigators. REGN-COV2, a neutralizing antibody cocktail, in outpatients with Covid-19. N Engl J Med 2021 Jan 21;384(3):238-251 [FREE Full text] [CrossRef] [Medline]
  49. Chen P, Nirula A, Heller B, Gottlieb RL, Boscia J, Morris J, BLAZE-1 Investigators. SARS-CoV-2 neutralizing antibody LY-CoV555 in outpatients with Covid-19. N Engl J Med 2021 Jan 21;384(3):229-237 [FREE Full text] [CrossRef] [Medline]
  50. Singh B, Ryan H, Kredo T, Chaplin M, Fletcher T. Chloroquine or hydroxychloroquine for prevention and treatment of COVID-19. Cochrane Database Syst Rev 2021 Feb 12;2:CD013587. [CrossRef] [Medline]
  51. Juul S, Nielsen EE, Feinberg J, Siddiqui F, Jørgensen CK, Barot E, et al. Interventions for treatment of COVID-19: a living systematic review with meta-analyses and trial sequential analyses (The LIVING Project). PLoS Med 2020 Sep;17(9):e1003293 [FREE Full text] [CrossRef] [Medline]
  52. Choi JY. Convalescent plasma therapy for coronavirus disease 2019. Infect Chemother 2020 Sep;52(3):307-316 [FREE Full text] [CrossRef] [Medline]
  53. Joyner MJ, Carter RE, Senefeld JW, Klassen SA, Mills JR, Johnson PW, et al. Convalescent plasma antibody levels and the risk of death from Covid-19. N Engl J Med 2021 Mar 18;384(11):1015-1027 [FREE Full text] [CrossRef] [Medline]
  54. Libster R, Pérez Marc G, Wappner D, Coviello S, Bianchi A, Braem V, Fundación INFANT–COVID-19 Group. Early high-titer plasma therapy to prevent severe Covid-19 in older adults. N Engl J Med 2021 Feb 18;384(7):610-618 [FREE Full text] [CrossRef] [Medline]
  55. Bloch E, Shoham S, Casadevall A, Sachais B, Shaz B, Winters J, et al. Deployment of convalescent plasma for the prevention and treatment of COVID-19. J Clin Invest 2020 Jun 01;130(6):2757-2765. [CrossRef] [Medline]
  56. Fung M, Nambiar A, Pandey S, Aldrich JM, Teraoka J, Freise C, et al. Treatment of immunocompromised COVID-19 patients with convalescent plasma. Transpl Infect Dis 2020 Sep 29:e13477 [FREE Full text] [CrossRef] [Medline]
  57. Wooding DJ, Bach H. Treatment of COVID-19 with convalescent plasma: lessons from past coronavirus outbreaks. Clin Microbiol Infect 2020 Oct;26(10):1436-1446 [FREE Full text] [CrossRef] [Medline]
  58. Malani AN, Sherbeck JP, Malani PN. Convalescent plasma and COVID-19. JAMA 2020 Aug 04;324(5):524. [CrossRef] [Medline]
  59. Tiberghien P, de Lamballerie X, Morel P, Gallian P, Lacombe K, Yazdanpanah Y. Collecting and evaluating convalescent plasma for COVID-19 treatment: why and how? Vox Sang 2020 Aug;115(6):488-494. [CrossRef] [Medline]
  60. Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gøtzsche PC, Ioannidis JPA, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ 2009 Jul 21;339:b2700 [FREE Full text] [CrossRef] [Medline]
  61. Grant MA, Booth A. A typology of reviews: an analysis of 14 review types and associated methodologies. Health Info Libr J 2009 Jun;26(2):91-108. [CrossRef] [Medline]
  62. Thomas B, Ciliska D, Dobbins M, Micucci S. A process for systematically reviewing the literature: providing the research evidence for public health nursing interventions. Worldviews Evid Based Nurs 2004;1(3):176-184. [CrossRef] [Medline]
  63. Hartman WR, Hess AS, Connor JP. Hospitalized COVID-19 patients treated with convalescent plasma in a mid-size city in the mid west. Res Square. Preprint posted online on August 6, 2020. [CrossRef] [Medline]
  64. Wan X, Wang W, Liu J, Tong T. Estimating the sample mean and standard deviation from the sample size, median, range and/or interquartile range. BMC Med Res Methodol 2014 Dec 19;14:135 [FREE Full text] [CrossRef] [Medline]
  65. Al Helali AA, Saeed GA, Elholiby TI, Kukkady MA, Mazrouei SSA. Radiological and clinical improvement in a patient with COVID-19 pneumonia postconvalescent plasma transfusion: a case report. Radiol Case Rep 2020 Nov;15(11):2171-2174 [FREE Full text] [CrossRef] [Medline]
  66. Anderson J, Schauer J, Bryant S, Graves C. The use of convalescent plasma therapy and remdesivir in the successful management of a critically ill obstetric patient with novel coronavirus 2019 infection: a case report. Case Rep Womens Health 2020 Jul;27:e00221 [FREE Full text] [CrossRef] [Medline]
  67. Bao Y, Lin SY, Cheng ZH, Xia J, Sun YP, Zhao Q, et al. Clinical features of COVID-19 in a young man with massive cerebral hemorrhage-case report. SN Compr Clin Med 2020 May 23:1-7 [FREE Full text] [CrossRef] [Medline]
  68. Çınar OE, Sayınalp B, Aladağ Karakulak E, Avşar Karataş A, Velet M, İnkaya A, et al. Convalescent (immune) plasma treatment in a myelodysplastic COVID-19 patient with disseminated tuberculosis. Transfus Apher Sci 2020 Oct;59(5):102821 [FREE Full text] [CrossRef] [Medline]
  69. Clark E, Guilpain P, Filip IL, Pansu N, Le Bihan C, Cartron G, et al. Convalescent plasma for persisting COVID-19 following therapeutic lymphocyte depletion: a report of rapid recovery. Br J Haematol 2020 Aug;190(3):e154-e156 [FREE Full text] [CrossRef] [Medline]
  70. Figlerowicz M, Mania A, Lubarski K, Lewandowska Z, Służewski W, Derwich K, et al. First case of convalescent plasma transfusion in a child with COVID-19-associated severe aplastic anemia. Transfus Apher Sci 2020 Oct;59(5):102866 [FREE Full text] [CrossRef] [Medline]
  71. Grisolia G, Franchini M, Glingani C, Inglese F, Garuti M, Beccaria M, et al. Convalescent plasma for coronavirus disease 2019 in pregnancy: a case report and review. Am J Obstet Gynecol MFM 2020 Aug;2(3):100174 [FREE Full text] [CrossRef] [Medline]
  72. Hahn M, Condori MEH, Totland A, Kristoffersen EK, Hervig TA. A patient with severe COVID-19 treated with convalescent plasma. Tidsskr Nor Laegeforen 2020 Sep 08;140(12):1 [FREE Full text] [CrossRef] [Medline]
  73. Hartman WR, Hess AS, Connor JP. Unusual cardiac presentation of COVID-19 and use of convalescent plasma. Case Rep Cardiol 2020;2020:8863195. [CrossRef] [Medline]
  74. Im JH, Nahm CH, Baek JH, Kwon HY, Lee J. Convalescent plasma therapy in coronavirus disease 2019: a case report and suggestions to overcome obstacles. J Korean Med Sci 2020 Jul 06;35(26):e239 [FREE Full text] [CrossRef] [Medline]
  75. Jafari R, Jonaidi-Jafari N, Dehghanpoor F, Saburi A. Convalescent plasma therapy in a pregnant COVID-19 patient with a dramatic clinical and imaging response: a case report. World J Radiol 2020 Jul 28;12(7):137-141 [FREE Full text] [CrossRef] [Medline]
  76. Jiang J, Miao Y, Zhao Y, Lu X, Zhou P, Zhou X, et al. Convalescent plasma therapy: helpful treatment of COVID-19 in a kidney transplant recipient presenting with severe clinical manifestations and complex complications. Clin Transplant 2020 Sep;34(9):e14025 [FREE Full text] [CrossRef] [Medline]
  77. Karataş A, İnkaya A, Demiroğlu H, Aksu S, Haziyev T, Çınar OE, et al. Prolonged viral shedding in a lymphoma patient with COVID-19 infection receiving convalescent plasma. Transfus Apher Sci 2020 Oct;59(5):102871 [FREE Full text] [CrossRef] [Medline]
  78. Khan A, Ajmal Z, Raval M, Tobin E. Concurrent diagnosis of acute myeloid leukemia and COVID-19: a management challenge. Cureus 2020 Aug 09;12(8):e9629 [FREE Full text] [CrossRef] [Medline]
  79. Kong Y, Cai C, Ling L, Zeng L, Wu M, Wu Y, et al. Successful treatment of a centenarian with coronavirus disease 2019 (COVID-19) using convalescent plasma. Transfus Apher Sci 2020 Oct;59(5):102820 [FREE Full text] [CrossRef] [Medline]
  80. Mira E, Yarce OA, Ortega C, Fernández S, Pascual NM, Gómez C, et al. Rapid recovery of a SARS-CoV-2-infected X-linked agammaglobulinemia patient after infusion of COVID-19 convalescent plasma. J Allergy Clin Immunol Pract 2020 Sep;8(8):2793-2795 [FREE Full text] [CrossRef] [Medline]
  81. Rodriguez Z, Shane A, Verkerke H, Lough C, Zimmerman M, Suthar M, et al. COVID-19 convalescent plasma clears SARS-CoV-2 refractory to remdesivir in an infant with congenital heart disease. Blood Adv 2020 Sep 22;4(18):4278-4281 [FREE Full text] [CrossRef] [Medline]
  82. Soleimani Z, Soleimani A. ADRS due to COVID-19 in midterm pregnancy: successful management with plasma transfusion and corticosteroids. J Matern Fetal Neonatal Med 2020 Jul 26:1-4. [CrossRef] [Medline]
  83. Xu T, Lin B, Chen C, Liu L, Xue Y. Non-optimal effectiveness of convalescent plasma transfusion and hydroxychloroquine in treating COVID-19: a case report. Virol J 2020 Jun 19;17(1):80 [FREE Full text] [CrossRef] [Medline]
  84. Zhang L, Pang R, Xue X, Bao J, Ye S, Dai Y, et al. Anti-SARS-CoV-2 virus antibody levels in convalescent plasma of six donors who have recovered from COVID-19. Aging (Albany NY) 2020 Apr 22;12(8):6536-6542 [FREE Full text] [CrossRef] [Medline]
  85. Ahn JY, Sohn Y, Lee SH, Cho Y, Hyun JH, Baek YJ, et al. Use of convalescent plasma therapy in two COVID-19 patients with acute respiratory distress syndrome in Korea. J Korean Med Sci 2020 Apr 13;35(14):e149 [FREE Full text] [CrossRef] [Medline]
  86. Abdullah H, Hama-Ali H, Ahmed S, Ali K, Karadakhy K, Mahmood S, et al. A severe refractory COVID-19 patient responding to convalescent plasma; a case series. Ann Med Surg (Lond) 2020 Aug;56:125-127 [FREE Full text] [CrossRef] [Medline]
  87. Bradfute S, Hurwitz I, Yingling A, Ye C, Cheng Q, Noonan T, et al. Severe acute respiratory syndrome coronavirus 2 neutralizing antibody titers in convalescent plasma and recipients in New Mexico: an open treatment study in patients with coronavirus disease 2019. J Infect Dis 2020 Oct 13;222(10):1620-1628 [FREE Full text] [CrossRef] [Medline]
  88. Diorio C, Anderson EM, McNerney KO, Goodwin EC, Chase JC, Bolton MJ, et al. Convalescent plasma for pediatric patients with SARS-CoV-2-associated acute respiratory distress syndrome. Pediatr Blood Cancer 2020 Nov;67(11):e28693. [CrossRef] [Medline]
  89. Enzmann MO, Erickson MP, Grindeland CJ, Lopez SMC, Hoover SE, Leedahl DD. Treatment and preliminary outcomes of 150 acute care patients with COVID-19 in a rural health system in the Dakotas. Epidemiol Infect 2020 Jun 22;148:e124 [FREE Full text] [CrossRef] [Medline]
  90. Erkurt MA, Sarici A, Berber İ, Kuku İ, Kaya E, Özgül M. Life-saving effect of convalescent plasma treatment in covid-19 disease: clinical trial from eastern Anatolia. Transfus Apher Sci 2020 Oct;59(5):102867 [FREE Full text] [CrossRef] [Medline]
  91. Gemici A, Bilgen H, Erdoğan C, Kansu A, Olmuşçelik O, Beköz HS, et al. A single center cohort of 40 severe COVID-19 patients who were treated with convalescent plasma. Turk J Med Sci 2020 Dec 17;50(8):1781-1785. [CrossRef] [Medline]
  92. Ibrahim D, Dulipsingh L, Zapatka L, Eadie R, Crowell R, Williams K, et al. Factors associated with good patient outcomes following convalescent plasma in COVID-19: a prospective phase II clinical trial. Infect Dis Ther 2020 Sep 20:1-14. [CrossRef] [Medline]
  93. Bobek I, Gopcsa L, Réti M, Bekő G, Hancz L, Lakatos B, et al. Successful administration of convalescent plasma in critically ill COVID-19 patients in Hungary: the first two cases. Orv Hetil 2020 Jul;161(27):1111-1121. [CrossRef] [Medline]
  94. Jin H, Reed JC, Liu ST, Ho H, Lopes JP, Ramsey NB, Mount Sinai Health System Convalescent Plasma Team. Three patients with X-linked agammaglobulinemia hospitalized for COVID-19 improved with convalescent plasma. J Allergy Clin Immunol Pract 2020;8(10):3594-3596.e3 [FREE Full text] [CrossRef] [Medline]
  95. Joyner M, Wright R, Fairweather D, Senefeld J, Bruno K, Klassen S, et al. Early safety indicators of COVID-19 convalescent plasma in 5000 patients. J Clin Invest 2020 Sep 01;130(9):4791-4797. [CrossRef] [Medline]
  96. Joyner M, Bruno K, Klassen S, Kunze K, Johnson P, Lesser E, et al. Safety update: COVID-19 convalescent plasma in 20,000 hospitalized patients. Mayo Clin Proc 2020 Sep;95(9):1888-1897 [FREE Full text] [CrossRef] [Medline]
  97. Joyner M, Senefeld J, Klassen S, Mills J, Johnson P, Theel E, et al. Effect of convalescent plasma on mortality among hospitalized patients with COVID-19: initial three-month experience. medRxiv. Preprint posted online on August 12, 2020. [CrossRef] [Medline]
  98. Liu M, Chen Z, Dai M, Yang J, Chen X, Chen D, et al. Lessons learned from early compassionate use of convalescent plasma on critically ill patients with Covid-19. Transfusion 2020 Oct;60(10):2210-2216 [FREE Full text] [CrossRef] [Medline]
  99. Maor Y, Cohen D, Paran N, Israely T, Ezra V, Axelrod O, et al. Compassionate use of convalescent plasma for treatment of moderate and severe pneumonia in COVID-19 patients and association with IgG antibody levels in donated plasma. EClinicalMedicine 2020 Sep;26:100525. [CrossRef] [Medline]
  100. Naeem S, Gohh R, Bayliss G, Cosgrove C, Farmakiotis D, Merhi B, et al. Successful recovery from COVID-19 in three kidney transplant recipients who received convalescent plasma therapy. Transpl Infect Dis 2021 Feb;23(1):e13451 [FREE Full text] [CrossRef] [Medline]
  101. Olivares-Gazca JC, Priesca-Marín JM, Ojeda-Laguna M, Garces-Eisele J, Soto-Olvera S, Palacios-Alonso A, et al. Infusion of convalescent plasma is associated with clinical improvement in critically ill patients with COVID-19: a pilot study. Rev Invest Clin 2020;72(3):159-164. [CrossRef] [Medline]
  102. Pal P, Ibrahim M, Niu A, Zwezdaryk KJ, Tatje E, Robinson WR, et al. Safety and efficacy of COVID-19 convalescent plasma in severe pulmonary disease: a report of 17 patients. Transfus Med 2020 Oct 19:1. [CrossRef] [Medline]
  103. Rahman F, Liu STH, Taimur S, Jacobs S, Sullivan T, Dunn D, et al. Treatment with convalescent plasma in solid organ transplant recipients with COVID-19: experience at large transplant center in New York City. Clin Transplant 2020 Dec;34(12):e14089. [CrossRef] [Medline]
  104. Salazar E, Perez KK, Ashraf M, Chen J, Castillo B, Christensen PA, et al. Treatment of coronavirus disease 2019 (COVID-19) patients with convalescent plasma. Am J Pathol 2020 Aug;190(8):1680-1690 [FREE Full text] [CrossRef] [Medline]
  105. Shen C, Wang Z, Zhao F, Yang Y, Li J, Yuan J, et al. Treatment of 5 critically ill patients with COVID-19 with convalescent plasma. JAMA 2020 Apr 28;323(16):1582-1589 [FREE Full text] [CrossRef] [Medline]
  106. Tremblay D, Seah C, Schneider T, Bhalla S, Feld J, Naymagon L, Mount Sinai Health System Convalescent Plasma Team. Convalescent plasma for the treatment of severe COVID-19 infection in cancer patients. Cancer Med 2020 Nov;9(22):8571-8578. [CrossRef] [Medline]
  107. Wei B, Hang X, Xie Y, Zhang Y, Wang J, Cao X, et al. Long-term positive severe acute respiratory syndrome coronavirus 2 ribonucleic acid and therapeutic effect of antivirals in patients with coronavirus disease: case reports. Rev Soc Bras Med Trop 2020;53:e20200372 [FREE Full text] [CrossRef] [Medline]
  108. Wang M, Yang X, Yang F, Zhu X, Sun Z, Bao P, et al. Convalescent plasma therapy in critically ill coronavirus disease 2019 patients with persistently positive nucleic acid test, case series report. Medicine (Baltimore) 2020 Sep 04;99(36):e21596. [CrossRef] [Medline]
  109. Wu Y, Hong K, Ruan L, Yang X, Zhang J, Xu J, et al. Patients with prolonged positivity of SARS-CoV-2 RNA benefit from convalescent plasma therapy: a retrospective study. Virol Sin 2020 Dec;35(6):768-775 [FREE Full text] [CrossRef] [Medline]
  110. Xi A, Zhuo M, Dai J, Ding Y, Ma X, Ma X, et al. Epidemiological and clinical characteristics of discharged patients infected with SARS-CoV-2 on the Qinghai Plateau. J Med Virol 2020 Nov;92(11):2528-2535 [FREE Full text] [CrossRef] [Medline]
  111. Ye M, Fu D, Ren Y, Wang F, Wang D, Zhang F, et al. Treatment with convalescent plasma for COVID-19 patients in Wuhan, China. J Med Virol 2020 Oct;92(10):1890-1901 [FREE Full text] [CrossRef] [Medline]
  112. Zhang B, Liu S, Tan T, Huang W, Dong Y, Chen L, et al. Treatment with convalescent plasma for critically ill patients with severe acute respiratory syndrome coronavirus 2 infection. Chest 2020 Jul;158(1):e9-e13 [FREE Full text] [CrossRef] [Medline]
  113. Zeng H, Wang D, Nie J, Liang H, Gu J, Zhao A, et al. The efficacy assessment of convalescent plasma therapy for COVID-19 patients: a multi-center case series. Signal Transduct Target Ther 2020 Oct 06;5(1):219. [CrossRef] [Medline]
  114. Abolghasemi H, Eshghi P, Cheraghali A, Imani Fooladi AA, Bolouki Moghaddam F, Imanizadeh S, et al. Clinical efficacy of convalescent plasma for treatment of COVID-19 infections: results of a multicenter clinical study. Transfus Apher Sci 2020 Oct;59(5):102875 [FREE Full text] [CrossRef] [Medline]
  115. Duan K, Liu B, Li C, Zhang H, Yu T, Qu J, et al. Effectiveness of convalescent plasma therapy in severe COVID-19 patients. Proc Natl Acad Sci U S A 2020 Apr 28;117(17):9490-9496 [FREE Full text] [CrossRef] [Medline]
  116. Hegerova L, Gooley T, Sweerus K, Maree C, Bailey N, Bailey M, et al. Use of convalescent plasma in hospitalized patients with COVID-19: case series. Blood 2020 Aug 06;136(6):759-762 [FREE Full text] [CrossRef] [Medline]
  117. Liu STH, Lin H, Baine I, Wajnberg A, Gumprecht JP, Rahman F, et al. Convalescent plasma treatment of severe COVID-19: a propensity score-matched control study. Nat Med 2020 Nov;26(11):1708-1713. [CrossRef] [Medline]
  118. Perotti C, Baldanti F, Bruno R, Del Fante C, Seminari E, Casari S, Covid-Plasma Task Force. Mortality reduction in 46 severe Covid-19 patients treated with hyperimmune plasma. A proof of concept single arm multicenter trial. Haematologica 2020 Dec 01;105(12):2834-2840. [CrossRef] [Medline]
  119. Rasheed A, Fatak D, Hashim H, Maulood M, Kabah K, Almusawi Y, et al. The therapeutic potential of convalescent plasma therapy on treating critically-ill COVID-19 patients residing in respiratory care units in hospitals in Baghdad, Iraq. Infez Med 2020 Sep 01;28(3):357-366 [FREE Full text] [Medline]
  120. Rogers R, Shehadeh F, Mylona E, Rich J, Neill M, Touzard-Romo F, et al. Convalescent plasma for patients with severe COVID-19: a matched cohort study. Clin Infect Dis 2020 Oct 10:ciaa1548 [FREE Full text] [CrossRef] [Medline]
  121. Salazar E, Christensen PA, Graviss EA, Nguyen DT, Castillo B, Chen J, et al. Treatment of coronavirus disease 2019 patients with convalescent plasma reveals a signal of significantly decreased mortality. Am J Pathol 2020 Nov;190(11):2290-2303 [FREE Full text] [CrossRef] [Medline]
  122. Xia X, Li K, Wu L, Wang Z, Zhu M, Huang B, et al. Improved clinical symptoms and mortality among patients with severe or critical COVID-19 after convalescent plasma transfusion. Blood 2020 Aug 06;136(6):755-759 [FREE Full text] [CrossRef] [Medline]
  123. Xiao K, Lin Y, Fan Z, Wen Y, Huang H, Wang M, et al. Effect of transfusion convalescent recovery plasma in patients with coronavirus disease 2019. Zhong Nan Da Xue Xue Bao Yi Xue Ban 2020 May 28;45(5):565-570 [FREE Full text] [CrossRef] [Medline]
  124. Zeng Q, Yu Z, Gou J, Li G, Ma S, Zhang G, et al. Effect of convalescent plasma therapy on viral shedding and survival in patients with coronavirus disease 2019. J Infect Dis 2020 Jun 16;222(1):38-43 [FREE Full text] [CrossRef] [Medline]
  125. Gharbharan A, Jordans CCE, Geurtsvankessel C, den Hollander JG, Karim F, Mollema FPN, et al. Convalescent plasma for COVID-19. A randomized clinical trial. medRxiv. Preprint posted online on July 3, 2020. [CrossRef]
  126. Li L, Zhang W, Hu Y, Tong X, Zheng S, Yang J, et al. Effect of convalescent plasma therapy on time to clinical improvement in patients with severe and life-threatening COVID-19: a randomized clinical trial. JAMA 2020 Aug 04;324(5):460-470 [FREE Full text] [CrossRef] [Medline]
  127. Alghamdi AN, Abdel-Moneim AS. Convalescent plasma: a potential life-saving therapy for coronavirus disease 2019 (COVID-19). Front Public Health 2020;8:437. [CrossRef] [Medline]
  128. Alzoughool F, Alanagreh L. Coronavirus drugs: using plasma from recovered patients as a treatment for COVID-19. Int J Risk Saf Med 2020;31(2):47-51 [FREE Full text] [CrossRef] [Medline]
  129. Borlongan MC, Borlongan MC, Sanberg PR. The disillusioned comfort with COVID-19 and the potential of convalescent plasma and cell therapy. Cell Transplant 2020;29:963689720940719 [FREE Full text] [CrossRef] [Medline]
  130. Cantore I, Valente P. Convalescent plasma from COVID 19 patients enhances intensive care unit survival rate. A preliminary report. Transfus Apher Sci 2020 Oct;59(5):102848 [FREE Full text] [CrossRef] [Medline]
  131. Casadevall A, Joyner MJ, Pirofski L. A randomized trial of convalescent plasma for COVID-19-potentially hopeful signals. JAMA 2020 Aug 04;324(5):455-457. [CrossRef] [Medline]
  132. Cheraghali AM, Abolghasemi H, Eshghi P. Management of COVID-19 virus infection by convalescent plasma. Iran J Allergy Asthma Immunol 2020 May 17;19(S1):3-6 [FREE Full text] [CrossRef] [Medline]
  133. Gazzaruso C, Valenti C, Coppola A, Gallotti P. Impact of convalescent and nonimmune plasma on mortality of patients with COVID-19: a potential role for antithrombin. Clin Microbiol Infect 2020 Sep 09:S1198-743X(20)30536-X [FREE Full text] [CrossRef] [Medline]
  134. Farhat RM, Mousa MA, Daas EJ, Glassberg MK. Treatment of COVID-19: perspective on convalescent plasma transfusion. Front Med (Lausanne) 2020;7:435. [CrossRef] [Medline]
  135. Focosi D, Tuccori M, Antonelli G, Maggi F. What is the optimal usage of coronavirus disease 2019 convalescent plasma donations? Clin Microbiol Infect 2021 Feb;27(2):163-165 [FREE Full text] [CrossRef] [Medline]
  136. Franchini M. Why should we use convalescent plasma for COVID-19? Eur J Intern Med 2020 Jul;77:150-151 [FREE Full text] [CrossRef] [Medline]
  137. Franchini M, Marano G, Velati C, Pati I, Pupella S, Liumbruno GM. Regarding international forum on hospital transfusion services' response to COVID-19. Vox Sang 2020 Nov;115(8):827 [FREE Full text] [CrossRef] [Medline]
  138. Franchini M, Del Fante C, Klersy C, Glingani C, Percivalle E, Baldanti F, et al. Challenges in the production of convalescent hyperimmune plasma in the age of COVID-19. Semin Thromb Hemost 2020 Oct;46(7):804-806 [FREE Full text] [CrossRef] [Medline]
  139. Franchini M, Marano G, Velati C, Pati I, Pupella S, Maria Liumbruno G. Operational protocol for donation of anti-COVID-19 convalescent plasma in Italy. Vox Sang 2021 Jan;116(1):136-137 [FREE Full text] [CrossRef] [Medline]
  140. Islam A, Rafiq S, Karim S, Laher I, Rashid H. Convalescent plasma therapy in the treatment of COVID-19: practical considerations: correspondence. Int J Surg 2020 Jul;79:204-205 [FREE Full text] [CrossRef] [Medline]
  141. Kesici S, Yavuz S, Bayrakci B. Get rid of the bad first: therapeutic plasma exchange with convalescent plasma for severe COVID-19. Proc Natl Acad Sci U S A 2020 Jun 09;117(23):12526-12527 [FREE Full text] [CrossRef] [Medline]
  142. Knudson CM, Jackson JB. COVID-19 convalescent plasma: phase 2. Transfusion 2020 Jun;60(6):1332-1333 [FREE Full text] [CrossRef] [Medline]
  143. Kumar S, Sharma V, Priya K. Battle against COVID-19: efficacy of convalescent plasma as an emergency therapy. Am J Emerg Med 2021 Mar;41:244-246 [FREE Full text] [CrossRef] [Medline]
  144. McAllister F, Mantegazza A, Garzón F, Rotbaum V, Remondino G, Vazquez Larsson M, et al. [Use of convalescent plasma for COVID-19 treatment. History and evidence]. Medicina (B Aires) 2020;80 Suppl 3:82-86 [FREE Full text] [Medline]
  145. Nnaji CA, Iwu CJ, Ndwandwe DE, Jordan P, Wiysonge CS. Convalescent plasma or hyperimmune immunoglobulin for people with COVID-19. S Afr Med J 2020 Jul 16;110(8):759-760 [FREE Full text] [Medline]
  146. Pau AK, Aberg J, Baker J, Belperio PS, Coopersmith C, Crew P, et al. Convalescent plasma for the treatment of COVID-19: perspectives of the National Institutes of Health COVID-19 Treatment Guidelines Panel. Ann Intern Med 2021 Jan;174(1):93-95 [FREE Full text] [CrossRef] [Medline]
  147. Rabelo-da-Ponte F, Silvello D, Scherer J, Ayala A, Klamt F. Convalescent plasma therapy in patients with severe or life-threatening COVID-19: a metadata analysis. J Infect Dis 2020 Oct 01;222(9):1575-1578 [FREE Full text] [CrossRef] [Medline]
  148. Roback JD, Guarner J. Convalescent plasma to treat COVID-19: possibilities and challenges. JAMA 2020 Apr 28;323(16):1561-1562. [CrossRef] [Medline]
  149. Roberts DJ, Miflin G, Estcourt L. Convalescent plasma for COVID-19: back to the future. Transfus Med 2020 Jun;30(3):174-176 [FREE Full text] [CrossRef] [Medline]
  150. Sabando Vélez BE, Plaza Meneses C, Felix M, Vanegas E, Mata VL, Romero Castillo H, et al. A practical approach for the compassionate use of convalescent plasma in patients with severe COVID-19 in developing countries. J Infect Dev Ctries 2020 Jul 31;14(7):737-741 [FREE Full text] [CrossRef] [Medline]
  151. Sahu KK, Jindal V, Siddiqui AD, Cerny J, Gerber JM. Convalescent plasma therapy: a passive therapy for an aggressive COVID-19. J Med Virol 2020 Nov;92(11):2251-2253 [FREE Full text] [CrossRef] [Medline]
  152. Sheikh S, Baig MA. Convalescent plasma: promise for COVID-19 pandemic. J Coll Physicians Surg Pak 2020 Jun;30(6):88. [CrossRef] [Medline]
  153. Syal K. COVID-19: herd immunity and convalescent plasma transfer therapy. J Med Virol 2020 Sep;92(9):1380-1382 [FREE Full text] [CrossRef] [Medline]
  154. Teixeira da Silva JA. Convalescent plasma: a possible treatment of COVID-19 in India. Med J Armed Forces India 2020 Apr;76(2):236-237 [FREE Full text] [CrossRef] [Medline]
  155. The Lancet Haematology. The resurgence of convalescent plasma therapy. Lancet Haematol 2020 May;7(5):e353 [FREE Full text] [CrossRef] [Medline]
  156. Tonn T, Corman VM, Johnsen M, Richter A, Rodionov RN, Drosten C, et al. Stability and neutralising capacity of SARS-CoV-2-specific antibodies in convalescent plasma. Lancet Microbe 2020 Jun;1(2):e63 [FREE Full text] [CrossRef] [Medline]
  157. Wong H, Lee C. Pivotal role of convalescent plasma in managing emerging infectious diseases. Vox Sang 2020 Oct;115(7):545-547 [FREE Full text] [CrossRef] [Medline]
  158. Yoo J. Convalescent plasma therapy for corona virus disease 2019: a long way to go but worth trying. J Korean Med Sci 2020 Apr 13;35(14):e150 [FREE Full text] [CrossRef] [Medline]
  159. Zhao Q, He Y. Challenges of convalescent plasma therapy on COVID-19. J Clin Virol 2020 Jun;127:104358 [FREE Full text] [CrossRef] [Medline]
  160. Zhu M, Hu K, Zhu Z. Use of convalescent plasma in COVID-19 patients in China. Transfus Clin Biol 2020 Aug;27(3):168-169 [FREE Full text] [CrossRef] [Medline]
  161. Tamburello A, Marando M. Immunoglobulins or convalescent plasma to tackle COVID-19: buying time to save lives - current situation and perspectives. Swiss Med Wkly 2020 Apr 20;150:w20264. [CrossRef] [Medline]
  162. Begum F, Ray U. Polymonoclonal (not polyclonal) antibodies derived from convalescent human B cell hybridomas might be a better therapeutic option than single target monoclonal antibodies. ACS Pharmacol Transl Sci 2020 Aug 14;3(4):786-787. [CrossRef] [Medline]
  163. Bloch E. Convalescent plasma to treat COVID-19. Blood 2020 Aug 06;136(6):654-655 [FREE Full text] [CrossRef] [Medline]
  164. Brown B. Response Letter: treatment for emerging viruses: convalescent plasma and COVID-19. Transfus Apher Sci 2021 Feb;60(1):102929 [FREE Full text] [CrossRef] [Medline]
  165. Casadevall A, Joyner M, Pirofski LA. Implications of COVI-19 antibody dynamics for immunity and convalescent plasma therapy. Clin Infect Dis 2020 Aug 17:ciaa1213 [FREE Full text] [CrossRef] [Medline]
  166. Casadevall A, Joyner M, Pirofski L. SARS-CoV-2 viral load and antibody responses: the case for convalescent plasma therapy. J Clin Invest 2020 Oct 01;130(10):5112-5114. [CrossRef] [Medline]
  167. Cunningham AC, Goh HP, Koh D. Treatment of COVID-19: old tricks for new challenges. Crit Care 2020 Mar 16;24(1):91 [FREE Full text] [CrossRef] [Medline]
  168. Dhanasekaran S, Vajravelu LK, Venkatesalu V. Risk-benefit analysis on the clinical significance of convalescent plasma therapy in the management of COVID-19. Postgrad Med J 2020 Aug 17:1. [CrossRef] [Medline]
  169. Dzik S. COVID-19 convalescent plasma: now is the time for better science. Transfus Med Rev 2020 Jul;34(3):141-144 [FREE Full text] [CrossRef] [Medline]
  170. Estcourt LJ, Roberts DJ. Convalescent plasma for covid-19. BMJ 2020 Sep 15;370:m3516. [CrossRef] [Medline]
  171. Farrugia A. Plasma from donors convalescent from SARS-CoV-2 infection-A matter of priorities. Transfus Clin Biol 2020 Aug;27(3):167-168 [FREE Full text] [CrossRef] [Medline]
  172. Fleming AB, Raabe V. Current studies of convalescent plasma therapy for COVID-19 may underestimate risk of antibody-dependent enhancement. J Clin Virol 2020 Jun;127:104388 [FREE Full text] [CrossRef] [Medline]
  173. Focosi D. Anti-A isohaemagglutinin titres and SARS-CoV-2 neutralization: implications for children and convalescent plasma selection. Br J Haematol 2020 Aug;190(3):e148-e150 [FREE Full text] [CrossRef] [Medline]
  174. Garraud O. Passive immunotherapy with convalescent plasma against COVID-19? What about the evidence base and clinical trials? Transfus Apher Sci 2020 Aug;59(4):102858 [FREE Full text] [CrossRef] [Medline]
  175. Gniadek TJ, Donnersberger D. COVID-19 convalescent plasma donor recruitment: beware the Faustian bargains. Transfusion 2020 Jul;60(7):1643-1644 [FREE Full text] [CrossRef] [Medline]
  176. Han G, Zhou Y. Thinking more about therapy with convalescent plasma for COVID-19 patients. Hum Vaccin Immunother 2020 Nov 01;16(11):2601-2603. [CrossRef] [Medline]
  177. Langhi DM, Santis GCD, Bordin JO. COVID-19 convalescent plasma transfusion. Hematol Transfus Cell Ther 2020;42(2):113-115 [FREE Full text] [CrossRef] [Medline]
  178. Lanza F, Seghatchian J. Reflection on passive immunotherapy in those who need most: some novel strategic arguments for obtaining safer therapeutic plasma or autologous antibodies from recovered COVID-19 infected patients. Br J Haematol 2020 Jul;190(1):e27-e29 [FREE Full text] [CrossRef] [Medline]
  179. Mahase E. Covid-19: US approves emergency use of convalescent plasma despite warnings over lack of evidence. BMJ 2020 Aug 25;370:m3327. [CrossRef] [Medline]
  180. Mahase E. Covid-19: US FDA fires spokesperson over misleading claims about convalescent plasma. BMJ 2020 Sep 02;370:m3400. [CrossRef] [Medline]
  181. Adiwinata Pawitan J. Convalescent plasma for COVID-19 considerations. Transfus Apher Sci 2021 Feb;60(1):102927 [FREE Full text] [CrossRef] [Medline]
  182. Prajapati S. Isopathic remedy prepared from convalescent plasma as a therapeutic option for COVID-19? Homeopathy 2020 Aug;109(3):184-185. [CrossRef] [Medline]
  183. Saverino D. Hyper-immune/convalescent plasma: an old option and a valid strategy for treatment of COVID-19? Minerva Med 2020 Aug;111(4):362-364 [FREE Full text] [CrossRef] [Medline]
  184. Stevens MP, Patel PK, Nori P. Antimicrobial stewardship programs and convalescent plasma for COVID-19: a new paradigm for preauthorization? Infect Control Hosp Epidemiol 2020 Sep 09:1-2 [FREE Full text] [CrossRef] [Medline]
  185. Tedder RS, Semple MG. Appropriate selection of convalescent plasma donors for COVID-19. Lancet Infect Dis 2021 Feb;21(2):168-169 [FREE Full text] [CrossRef] [Medline]
  186. Van den Berg K, Vermeulen M, Glatt T, Wasserman S, Barrett C, Peter J, et al. COVID-19: convalescent plasma as a potential therapy. S Afr Med J 2020 Jun 04;110(7):562-563. [Medline]
  187. Verkerke HP, Maier CL. Towards characterized convalescent plasma for COVID-19: the dose matters. EClinicalMedicine 2020 Sep;26:100545 [FREE Full text] [CrossRef] [Medline]
  188. Xi Y. Convalescent plasma therapy for COVID-19: a tried-and-true old strategy? Signal Transduct Target Ther 2020 Sep 15;5(1):203. [CrossRef] [Medline]
  189. Zeng F, Chen X, Deng G. Convalescent plasma for patients with COVID-19. Proc Natl Acad Sci U S A 2020 Jun 09;117(23):12528 [FREE Full text] [CrossRef] [Medline]
  190. Zylberman V, Sanguineti S, Pontoriero A, Higa S, Cerutti M, Morrone Seijo SM, et al. Development of a hyperimmune equine serum therapy for COVID-19 in Argentina. Medicina (B Aires) 2020;80 Suppl 3:1-6 [FREE Full text] [Medline]
  191. Caccamo N, Sullivan LC, Brooks AG, Dieli F. Harnessing HLA-E-restricted CD8 T lymphocytes for adoptive cell therapy of patients with severe COVID-19. Br J Haematol 2020 Aug;190(4):e185-e187 [FREE Full text] [CrossRef] [Medline]
  192. Ferreira LMR, Mostajo-Radji MA. Plasma-based COVID-19 treatments in low- and middle-income nations pose a high risk of an HIV epidemic. NPJ Vaccines 2020 Jul 06;5(1):58. [CrossRef] [Medline]
  193. Joob BV, Wiwanitkit V. Convalescent plasma and covid-19 treatment. Minerva Med 2020 Jun 12:1 [FREE Full text] [CrossRef] [Medline]
  194. Sanfilippo F, La Rosa V, Oliveri F, Astuto M. Convalescent plasma for COVID-19: the risk of pulmonary embolism should not be underestimated!. Crit Care 2020 Aug 28;24(1):531 [FREE Full text] [CrossRef] [Medline]
  195. Sanfilippo F, La Rosa V, Oliveri F, Astuto M. COVID-19, hypercoagulability, and cautiousness with convalescent plasma. Am J Respir Crit Care Med 2021 Jan 15;203(2):257-258 [FREE Full text] [CrossRef] [Medline]
  196. Wiwanitkit V. Convalescent plasma therapy in the treatment of COVID-19: some considerations: correspondence. Int J Surg 2020 Aug;80:26 [FREE Full text] [CrossRef] [Medline]
  197. Barone PR, DeSimone RA. Convalescent plasma to treat coronavirus disease 2019 (COVID-19): considerations for clinical trial design. Transfusion 2020 Jun;60(6):1123-1127 [FREE Full text] [CrossRef] [Medline]
  198. Majbour NO, El-Agnaf O. Plasma-derived therapy: can the survivors of COVID-19 help the defenseless? Diagnosis (Berl) 2020 Nov 18;7(4):373-376. [CrossRef] [Medline]
  199. Brown BL, McCullough J. Treatment for emerging viruses: convalescent plasma and COVID-19. Transfus Apher Sci 2020 Jun;59(3):102790 [FREE Full text] [CrossRef] [Medline]
  200. Cao H, Shi Y. Convalescent plasma: possible therapy for novel coronavirus disease 2019. Transfusion 2020 May;60(5):1078-1083 [FREE Full text] [CrossRef] [Medline]
  201. Zheng K, Liao G, Lalu MM, Tinmouth A, Fergusson DA, Allan DS. A scoping review of registered clinical trials of convalescent plasma for COVID-19 and a Framework for Accelerated Synthesis of Trial Evidence (FAST Evidence). Transfus Med Rev 2020 Jul;34(3):158-164 [FREE Full text] [CrossRef] [Medline]
  202. de Alwis R, Chen S, Gan ES, Ooi EE. Impact of immune enhancement on Covid-19 polyclonal hyperimmune globulin therapy and vaccine development. EBioMedicine 2020 May;55:102768 [FREE Full text] [CrossRef] [Medline]
  203. Fischer JC, Zänker K, van Griensven M, Schneider M, Kindgen-Milles D, Knoefel WT, et al. The role of passive immunization in the age of SARS-CoV-2: an update. Eur J Med Res 2020 May 13;25(1):16 [FREE Full text] [CrossRef] [Medline]
  204. Mucha SR, Quraishy N. Convalescent plasma for COVID-19: promising, not proven. Cleve Clin J Med 2020 Nov 02;87(11):664-670 [FREE Full text] [CrossRef] [Medline]
  205. Chai K, Valk S, Piechotta V, Kimber C, Monsef I, Doree C, et al. Convalescent plasma or hyperimmune immunoglobulin for people with COVID-19: a living systematic review. Cochrane Database Syst Rev 2020 Oct 12;10:CD013600. [CrossRef] [Medline]
  206. Devasenapathy N, Ye Z, Loeb M, Fang F, Najafabadi BT, Xiao Y, et al. Efficacy and safety of convalescent plasma for severe COVID-19 based on evidence in other severe respiratory viral infections: a systematic review and meta-analysis. CMAJ 2020 Jul 06;192(27):E745-E755 [FREE Full text] [CrossRef] [Medline]
  207. Piechotta V, Chai K, Valk S, Doree C, Monsef I, Wood E, et al. Convalescent plasma or hyperimmune immunoglobulin for people with COVID-19: a living systematic review. Cochrane Database Syst Rev 2020 Jul 10;7:CD013600. [CrossRef] [Medline]
  208. Sarkar S, Soni KD, Khanna P. Convalescent plasma is a clutch at straws in COVID-19 management! A systematic review and meta-analysis. J Med Virol 2021 Feb;93(2):1111-1118 [FREE Full text] [CrossRef] [Medline]
  209. Sun M, Xu Y, He H, Zhang L, Wang X, Qiu Q, et al. A potentially effective treatment for COVID-19: a systematic review and meta-analysis of convalescent plasma therapy in treating severe infectious disease. Int J Infect Dis 2020 Sep;98:334-346 [FREE Full text] [CrossRef] [Medline]
  210. Abdollahi H, Shiri I, Bevelacqua JJ, Jafarzadeh A, Rahmim A, Zaidi H, et al. Low dose radiation therapy and convalescent plasma: how a hybrid method may maximize benefits for COVID-19 patients. J Biomed Phys Eng 2020 Aug;10(4):387-394 [FREE Full text] [CrossRef] [Medline]
  211. Annamaria P, Eugenia Q, Paolo S. Anti-SARS-CoV-2 hyperimmune plasma workflow. Transfus Apher Sci 2020 Oct;59(5):102850 [FREE Full text] [CrossRef] [Medline]
  212. Anudeep T, Jeyaraman M, Shetty D, Raj H, Ajay S, Rajeswari S, et al. Convalescent plasma as a plausible therapeutic option for nCOVID-19 – a review. J Clin Trials 2020;10(3):1-7.
  213. Venkat Kumar G, Jeyanthi V, Ramakrishnan S. A short review on antibody therapy for COVID-19. New Microbes New Infect 2020 May;35:100682 [FREE Full text] [CrossRef] [Medline]
  214. Gasparyan AY, Misra DP, Yessirkepov M, Zimba O. Perspectives of immune therapy in coronavirus disease 2019. J Korean Med Sci 2020 May 11;35(18):e176 [FREE Full text] [CrossRef] [Medline]
  215. Iftikhar A, Jabeen F, Manzoor M, Younis T, Shaheen M. Passive immunization: paradoxical and traditional method for new pandemic challenge COVID-19. Acta Microbiol Immunol Hung 2020 Jul 03;67(2):87-90. [CrossRef] [Medline]
  216. Li S, Zhao H, Sun Y, Wang P, Li H, Duan M. [Application of convalescent plasma for the treatment of adult patients with coronavirus disease 2019]. Zhonghua Wei Zhong Bing Ji Jiu Yi Xue 2020 Jun;32(6):646-651. [CrossRef] [Medline]
  217. Lindholm PF, Ramsey G, Kwaan HC. Passive immunity for coronavirus disease 2019:a commentary on therapeutic aspects including convalescent plasma. Semin Thromb Hemost 2020 Oct;46(7):796-803 [FREE Full text] [CrossRef] [Medline]
  218. Murphy M, Estcourt L, Grant-Casey J, Dzik S. International survey of trials of convalescent plasma to treat COVID-19 infection. Transfus Med Rev 2020 Jul;34(3):151-157 [FREE Full text] [CrossRef] [Medline]
  219. Sayinalp B, Çinar OE, Haznedaroğlu İ. Perspectives for immune plasma treatment of COVID-19. Turk J Med Sci 2021 Feb 26;51(1):1-9. [CrossRef] [Medline]
  220. Subbarao K, Mordant F, Rudraraju R. Convalescent plasma treatment for COVID-19: tempering expectations with the influenza experience. Eur J Immunol 2020 Oct;50(10):1447-1453. [CrossRef] [Medline]
  221. Pawar AY, Hiray AP, Sonawane DD, Bhambar RS, Derle DV, Ahire YS. Convalescent plasma: a possible treatment protocol for COVID- 19 patients suffering from diabetes or underlying liver diseases. Diabetes Metab Syndr 2020;14(4):665-669 [FREE Full text] [CrossRef] [Medline]
  222. Bakhtawar N, Usman M, Khan M. Convalescent plasma therapy and its effects on COVID-19 patient outcomes: a systematic review of current literature. Cureus 2020 Aug 03;12(8):e9535 [FREE Full text] [CrossRef] [Medline]
  223. Chen B, Xia R. Early experience with convalescent plasma as immunotherapy for COVID-19 in China: knowns and unknowns. Vox Sang 2020 Aug;115(6):507-514 [FREE Full text] [CrossRef] [Medline]
  224. Rajendran K, Krishnasamy N, Rangarajan J, Rathinam J, Natarajan M, Ramachandran A. Convalescent plasma transfusion for the treatment of COVID-19: systematic review. J Med Virol 2020 Sep;92(9):1475-1483 [FREE Full text] [CrossRef] [Medline]
  225. Valk S, Piechotta V, Chai K, Doree C, Monsef I, Wood E, et al. Convalescent plasma or hyperimmune immunoglobulin for people with COVID-19: a rapid review. Cochrane Database Syst Rev 2020 May 14;5:CD013600. [CrossRef] [Medline]
  226. Focosi D, Farrugia A. The art of the possible in approaching efficacy trials for COVID19 convalescent plasma. Int J Infect Dis 2021 Jan;102:244-246 [FREE Full text] [CrossRef] [Medline]
  227. Nagoba B, Gavkare A, Jamadar N, Mumbre S, Selkar S. Positive aspects, negative aspects and limitations of plasma therapy with special reference to COVID-19. J Infect Public Health 2020 Dec;13(12):1818-1822 [FREE Full text] [CrossRef] [Medline]
  228. Psaltopoulou T, Sergentanis TN, Pappa V, Politou M, Terpos E, Tsiodras S, et al. The emerging role of convalescent plasma in the treatment of COVID-19. Hemasphere 2020 Jun;4(3):e409 [FREE Full text] [CrossRef] [Medline]
  229. Khulood D, Adil MS, Sultana R, Nimra. Convalescent plasma appears efficacious and safe in COVID-19. Ther Adv Infect Dis 2020;7:2049936120957931 [FREE Full text] [CrossRef] [Medline]
  230. Chua Vi Long K, Sayed A, Karki P, Acharya Y. Convalescent blood products in COVID-19: a narrative review. Ther Adv Infect Dis 2020;7:2049936120960646 [FREE Full text] [CrossRef] [Medline]
  231. Ouyang J, Isnard S, Lin J, Fombuena B, Peng X, Routy J, et al. Convalescent plasma: the relay baton in the race for coronavirus disease 2019 treatment. Front Immunol 2020;11:570063. [CrossRef] [Medline]
  232. Piyush R, Rajarshi K, Khan R, Ray S. Convalescent plasma therapy: a promising coronavirus disease 2019 treatment strategy. Open Biol 2020 Sep;10(9):200174 [FREE Full text] [CrossRef] [Medline]
  233. Rojas M, Rodríguez Y, Monsalve DM, Acosta-Ampudia Y, Camacho B, Gallo JE, et al. Convalescent plasma in Covid-19: possible mechanisms of action. Autoimmun Rev 2020 Jul;19(7):102554 [FREE Full text] [CrossRef] [Medline]
  234. Selvi V. Convalescent plasma: a challenging tool to treat COVID-19 patients-a lesson from the past and new perspectives. Biomed Res Int 2020;2020:2606058. [CrossRef] [Medline]
  235. Sharun K, Tiwari R, Iqbal Yatoo M, Patel SK, Natesan S, Dhama J, et al. Antibody-based immunotherapeutics and use of convalescent plasma to counter COVID-19: advances and prospects. Expert Opin Biol Ther 2020 Sep;20(9):1033-1046. [CrossRef] [Medline]
  236. Sullivan HC, Roback JD. Convalescent plasma: therapeutic hope or hopeless strategy in the SARS-CoV-2 pandemic. Transfus Med Rev 2020 Jul;34(3):145-150 [FREE Full text] [CrossRef] [Medline]
  237. Yiğenoğlu TN, Hacıbekiroğlu T, Berber, Dal MS, Baştürk A, Namdaroğlu S, et al. Convalescent plasma therapy in patients with COVID-19. J Clin Apher 2020 Aug;35(4):367-373 [FREE Full text] [CrossRef] [Medline]
  238. Accorsi P, Berti P, de Angelis V, De Silvestro G, Mascaretti L, Ostuni A, Italian Society for Transfusion Medicine Immunohaematology (SIMTI) Italian Society for Hemapheresis cell Manipulation (SIdEM). Position paper on the preparation of immune plasma to be used in the treatment of patients with COVID-19. Transfus Apher Sci 2020 Aug;59(4):102817 [FREE Full text] [CrossRef] [Medline]
  239. Albalawi M, Zaidi SZA, AlShehry N, AlAskar A, Zaidi ARZ, Abdallah RNM, et al. Safety and efficacy of convalescent plasma to treat severe COVID-19: protocol for the Saudi collaborative multicenter phase II study. JMIR Res Protoc 2020 Oct 02;9(10):e23543 [FREE Full text] [CrossRef] [Medline]
  240. Al-Riyami AZ, Schäfer R, van den Berg K, Bloch EM, Estcourt LJ, Goel R, et al. Clinical use of convalescent plasma in the COVID-19 pandemic: a transfusion-focussed gap analysis with recommendations for future research priorities. Vox Sang 2021 Jan;116(1):88-98 [FREE Full text] [CrossRef] [Medline]
  241. Albahri O, Al-Obaidi JR, Zaidan A, Albahri A, Zaidan B, Salih MM, et al. Helping doctors hasten COVID-19 treatment: towards a rescue framework for the transfusion of best convalescent plasma to the most critical patients based on biological requirements via ml and novel MCDM methods. Comput Methods Programs Biomed 2020 Nov;196:105617 [FREE Full text] [CrossRef] [Medline]
  242. Bloch EM, Goel R, Wendel S, Burnouf T, Al-Riyami AZ, Ang AL, et al. Guidance for the procurement of COVID-19 convalescent plasma: differences between high- and low-middle-income countries. Vox Sang 2021 Jan;116(1):18-35 [FREE Full text] [CrossRef] [Medline]
  243. Blackall D, Wulff S, Roettger T, Jacobs L, Lacasse A, Patri M, et al. Rapid establishment of a COVID-19 convalescent plasma program in a regional health care delivery network. Transfusion 2020 Oct;60(10):2203-2209 [FREE Full text] [CrossRef] [Medline]
  244. Budhai A, Wu AA, Hall L, Strauss D, Paradiso S, Alberigo J, et al. How did we rapidly implement a convalescent plasma program? Transfusion 2020 Jul;60(7):1348-1355 [FREE Full text] [CrossRef] [Medline]
  245. Chowdhury FR, Hoque A, Chowdhury FUH, Amin MR, Rahim A, Rahman MM, et al. Convalescent plasma transfusion therapy in severe COVID-19 patients- a safety, efficacy and dose response study: a structured summary of a study protocol of a phase II randomized controlled trial. Trials 2020 Oct 26;21(1):883 [FREE Full text] [CrossRef] [Medline]
  246. Eckhardt CM, Cummings MJ, Rajagopalan KN, Borden S, Bitan ZC, Wolf A, et al. Evaluating the efficacy and safety of human anti-SARS-CoV-2 convalescent plasma in severely ill adults with COVID-19: a structured summary of a study protocol for a randomized controlled trial. Trials 2020 Jun 08;21(1):499 [FREE Full text] [CrossRef] [Medline]
  247. Janssen M, Schäkel U, Djuka Fokou C, Krisam J, Stermann J, Kriegsmann K, et al. A randomized open label phase-II clinical trial with or without infusion of plasma from subjects after convalescence of SARS-CoV-2 infection in high-risk patients with confirmed severe SARS-CoV-2 disease (RECOVER): a structured summary of a study protocol for a randomised controlled trial. Trials 2020 Oct 06;21(1):828 [FREE Full text] [CrossRef] [Medline]
  248. Epstein J, Burnouf T. Points to consider in the preparation and transfusion of COVID-19 convalescent plasma. Vox Sang 2020 Aug;115(6):485-487 [FREE Full text] [CrossRef] [Medline]
  249. Epstein J, Smid WM, Wendel S, Somuah D, Burnouf T. Use of COVID-19 convalescent plasma in low- and middle-income countries: a call for ethical principles and the assurance of quality and safety. Vox Sang 2021 Jan;116(1):13-14 [FREE Full text] [CrossRef] [Medline]
  250. Hassan MO, Osman AA, Elbasit HEA, Hassan HE, Rufai H, Satti MM, et al. Convalescent plasma as a treatment modality for coronavirus disease 2019 in Sudan. Transfus Apher Sci 2020 Dec;59(6):102918 [FREE Full text] [CrossRef] [Medline]
  251. Ipe TS, Le T, Quinn B, Kellar S, Clark M, Carlisle S, et al. Provision of COVID-19 convalescent plasma in a resource-constrained state. Transfusion 2020 Dec;60(12):2828-2833 [FREE Full text] [CrossRef] [Medline]
  252. Li L, Yang R, Wang J, Lv Q, Ren M, Zhao L, et al. Feasibility of a pilot program for COVID-19 convalescent plasma collection in Wuhan, China. Transfusion 2020 Aug;60(8):1773-1777 [FREE Full text] [CrossRef] [Medline]
  253. Pei S, Yuan X, Zhang Z, Yao R, Xie Y, Shen M, et al. Convalescent plasma to treat COVID-19: Chinese strategy and experiences. medRxiv. Preprint posted online on April 11, 2020. [CrossRef]
  254. Perotti C, Del Fante C, Baldanti F, Franchini M, Percivalle E, Vecchio Nepita E, et al. Plasma from donors recovered from the new coronavirus 2019 as therapy for critical patients with COVID-19 (COVID-19 plasma study): a multicentre study protocol. Intern Emerg Med 2020 Aug;15(5):819-824. [CrossRef] [Medline]
  255. Seghatchian J, Lanza F. Convalescent plasma, an apheresis research project targeting and motivating the fully recovered COVID 19 patients: a rousing message of clinical benefit to both donors and recipients alike. Transfus Apher Sci 2020 Jun;59(3):102794 [FREE Full text] [CrossRef] [Medline]
  256. Yılmaz S, Ertuğrul Örüç N, Özcebe O, Azap A, Çetin AT, Yenicesu İ, et al. Regulatory consideration on preparation and clinical use of COVID-19 convalescent plasma. Transfus Apher Sci 2020 Oct;59(5):102846 [FREE Full text] [CrossRef] [Medline]
  257. Amanat F, Stadlbauer D, Strohmeier S, Nguyen THO, Chromikova V, McMahon M, et al. A serological assay to detect SARS-CoV-2 seroconversion in humans. Nat Med 2020 Jul;26(7):1033-1036. [CrossRef] [Medline]
  258. Byrnes J, Zhou X, Lui I, Elledge S, Glasgow J, Lim S, et al. A SARS-CoV-2 serological assay to determine the presence of blocking antibodies that compete for human ACE2 binding. medRxiv. Preprint posted online on May 29, 2020. [CrossRef] [Medline]
  259. Gattinger P, Borochova K, Dorofeeva Y, Henning R, Kiss R, Kratzer B, et al. Antibodies in serum of convalescent patients following mild COVID-19 do not always prevent virus-receptor binding. Allergy 2021 Mar;76(3):878-883. [CrossRef] [Medline]
  260. DomBourian MG, Annen K, Huey L, Andersen G, Merkel PA, Jung S, et al. Analysis of COVID-19 convalescent plasma for SARS-CoV-2 IgG using two commercial immunoassays. J Immunol Methods 2020 Nov;486:112837 [FREE Full text] [CrossRef] [Medline]
  261. Ding S, Laumaea A, Gasser R, Medjahed H, Pancera M, Stamatatos L, et al. Antibody binding to SARS-CoV-2 S glycoprotein correlates with, but does not predict neutralization. bioRxiv. Preprint posted online on September 08, 2020. [CrossRef] [Medline]
  262. Ianevski A, Yao R, Fenstad M, Biza S, Zusinaite E, Reisberg T, et al. Potential antiviral options against SARS-CoV-2 infection. Viruses 2020 Jun 13;12(6):642 [FREE Full text] [CrossRef] [Medline]
  263. Schmidt F, Weisblum Y, Muecksch F, Hoffmann H, Michailidis E, Lorenzi J, et al. Measuring SARS-CoV-2 neutralizing antibody activity using pseudotyped and chimeric viruses. J Exp Med 2020 Nov 02;217(11):e20201181 [FREE Full text] [CrossRef] [Medline]
  264. Wang X, Guo X, Xin Q, Pan Y, Hu Y, Li J, et al. Neutralizing antibody responses to severe acute respiratory syndrome coronavirus 2 in coronavirus disease 2019 inpatients and convalescent patients. Clin Infect Dis 2020 Dec 17;71(10):2688-2694 [FREE Full text] [CrossRef] [Medline]
  265. Muruato A, Fontes-Garfias C, Ren P, Garcia-Blanco M, Menachery V, Xie X, et al. A high-throughput neutralizing antibody assay for COVID-19 diagnosis and vaccine evaluation. Nat Commun 2020 Aug 13;11(1):4059. [CrossRef] [Medline]
  266. Ragnesola B, Jin D, Lamb CC, Shaz BH, Hillyer CD, Luchsinger LL. COVID19 antibody detection using lateral flow assay tests in a cohort of convalescent plasma donors. BMC Res Notes 2020 Aug 06;13(1):372 [FREE Full text] [CrossRef] [Medline]
  267. Yang HS, Racine-Brzostek SE, Lee WT, Hunt D, Yee J, Chen Z, et al. SARS-CoV-2 antibody characterization in emergency department, hospitalized and convalescent patients by two semi-quantitative immunoassays. Clin Chim Acta 2020 Oct;509:117-125 [FREE Full text] [CrossRef] [Medline]
  268. de Assis RR, Jain A, Nakajima R, Jasinskas A, Felgner J, Obiero J, Prometheus Study Group, et al. Analysis of SARS-CoV-2 antibodies in COVID-19 convalescent plasma using a coronavirus antigen microarray. bioRxiv. Preprint posted online on May 8, 2020. [CrossRef] [Medline]
  269. Dulipsingh L, Ibrahim D, Schaefer EJ, Crowell R, Diffenderfer MR, Williams K, et al. SARS-CoV-2 serology and virology trends in donors and recipients of convalescent plasma. Transfus Apher Sci 2020 Dec;59(6):102922. [CrossRef] [Medline]
  270. Ikegami S, Benirschke R, Flanagan T, Tanna N, Klein T, Elue R, et al. Persistence of SARS-CoV-2 nasopharyngeal swab PCR positivity in COVID-19 convalescent plasma donors. Transfusion 2020 Dec;60(12):2962-2968 [FREE Full text] [CrossRef] [Medline]
  271. Ma H, Zhao D, Zeng W, Yang Y, Hu X, Zhou P, et al. Decline of SARS-CoV-2-specific IgG, IgM and IgA in convalescent COVID-19 patients within 100 days after hospital discharge. Sci China Life Sci 2020 Aug 28:1-4 [FREE Full text] [CrossRef] [Medline]
  272. Danh K, Karp D, Robinson P, Seftel D, Stone M, Simmons G, et al. Detection of SARS-CoV-2 neutralizing antibodies with a cell-free PCR assay. medRxiv. Preprint posted online on June 2, 2020. [CrossRef] [Medline]
  273. Hartman WR, Hess AS, Connor JP. Persistent viral RNA shedding after COVID-19 symptom resolution in older convalescent plasma donors. Transfusion 2020 Oct;60(10):2189-2191 [FREE Full text] [CrossRef] [Medline]
  274. Abe K, Li Z, Samson R, Samavarchi-Tehrani P, Valcourt E, Wood H, et al. A simple protein-based surrogate neutralization assay for SARS-CoV-2. JCI Insight 2020 Oct 02;5(19):e142362. [CrossRef] [Medline]
  275. Beaudoin-Bussières G, Laumaea A, Anand SP, Prévost J, Gasser R, Goyette G, et al. Decline of humoral responses against SARS-CoV-2 spike in convalescent individuals. mBio 2020 Oct 16;11(5):e02590-e02520 [FREE Full text] [CrossRef] [Medline]
  276. Benner S, Patel E, Laeyendecker O, Pekosz A, Littlefield K, Eby Y, et al. SARS-CoV-2 antibody avidity responses in COVID-19 patients and convalescent plasma donors. J Infect Dis 2020 Nov 13;222(12):1974-1984 [FREE Full text] [CrossRef] [Medline]
  277. Boonyaratanakornkit J, Morishima C, Selke S, Zamora D, McGuffin S, Shapiro A, et al. Clinical, laboratory, and temporal predictors of neutralizing antibodies to SARS-CoV-2 after COVID-19. medRxiv. Preprint posted online on October 21, 2020. [CrossRef] [Medline]
  278. Gniadek TJ, Thiede JM, Matchett WE, Gress AR, Pape KA, Fiege JK, et al. SARS-CoV-2 neutralization and serology testing of COVID-19 convalescent plasma from donors with nonsevere disease. Transfusion 2021 Jan;61(1):17-23. [CrossRef] [Medline]
  279. Patel EU, Bloch EM, Clarke W, Hsieh Y, Boon D, Eby Y, et al. Comparative performance of five commercially available serologic assays to detect antibodies to SARS-CoV-2 and identify individuals with high neutralizing titers. medRxiv. September 2, 2020 2021. [CrossRef]
  280. Harvala H, Mehew J, Robb M, Ijaz S, Dicks S, Patel M, NHS Blood and Transplant Convalescent Plasma Testing Group. Convalescent plasma treatment for SARS-CoV-2 infection: analysis of the first 436 donors in England, 22 April to 12 May 2020. Euro Surveill 2020 Jul;25(28):2001260 [FREE Full text] [CrossRef] [Medline]
  281. Wendel S, Kutner JM, Machado R, Fontão-Wendel R, Bub C, Fachini R, et al. Screening for SARS-CoV-2 antibodies in convalescent plasma in Brazil: preliminary lessons from a voluntary convalescent donor program. Transfusion 2020 Dec;60(12):2938-2951 [FREE Full text] [CrossRef] [Medline]
  282. Zeng C, Evans J, Pearson R, Qu P, Zheng Y, Robinson R, et al. Neutralizing antibody against SARS-CoV-2 spike in COVID-19 patients, health care workers and convalescent plasma donors: a cohort study using a rapid and sensitive high-throughput neutralization assay. medRxiv. Preprint posted online on August 4, 2020. [CrossRef] [Medline]
  283. Dogan M, Kozhaya L, Placek L, Gunter C, Yigit M, Hardy R, et al. Novel SARS-CoV-2 specific antibody and neutralization assays reveal wide range of humoral immune response during COVID-19. medRxiv. Preprint posted online on October 14, 2020. [CrossRef] [Medline]
  284. Jungbauer C, Weseslindtner L, Weidner L, Gänsdorfer S, Farcet MR, Gschaider-Reichhart E, et al. Characterization of 100 sequential SARS-CoV-2 convalescent plasma donations. Transfusion 2021 Jan;61(1):12-16 [FREE Full text] [CrossRef] [Medline]
  285. Li L, Tong X, Chen H, He R, Lv Q, Yang R, et al. Characteristics and serological patterns of COVID-19 convalescent plasma donors: optimal donors and timing of donation. Transfusion 2020 Aug;60(8):1765-1772 [FREE Full text] [CrossRef] [Medline]
  286. Ni L, Ye F, Cheng ML, Feng Y, Deng YQ, Zhao H, et al. Detection of SARS-CoV-2-specific humoral and cellular immunity in COVID-19 convalescent individuals. Immunity 2020 Jun 16;52(6):971-977.e3 [FREE Full text] [CrossRef] [Medline]
  287. Robbiani D, Gaebler C, Muecksch F, Lorenzi J, Wang Z, Cho A, et al. Convergent antibody responses to SARS-CoV-2 infection in convalescent individuals. bioRxiv. Preprint posted online on May 22, 2020. [CrossRef] [Medline]
  288. Salazar E, Kuchipudi S, Christensen P, Eagar T, Yi X, Zhao P, et al. Relationship between anti-spike protein antibody titers and SARS-CoV-2 virus neutralization in convalescent plasma. bioRxiv. Preprint posted online on June 9, 2020. [CrossRef] [Medline]
  289. Weidner L, Gänsdorfer S, Unterweger S, Weseslindtner L, Drexler C, Farcet M, et al. Quantification of SARS-CoV-2 antibodies with eight commercially available immunoassays. J Clin Virol 2020 Aug;129:104540 [FREE Full text] [CrossRef] [Medline]
  290. Natarajan H, Crowley A, Butler S, Xu S, Weiner J, Bloch E, et al. SARS-CoV-2 antibody signatures robustly predict diverse antiviral functions relevant for convalescent plasma therapy. medRxiv. Preprint posted online on September 18, 2020. [CrossRef] [Medline]
  291. Stadlbauer D, Baine I, Amanat F, Jiang K, Lally K, Krammer F, et al. Anti-SARS-CoV-2 spike antibodies are stable in convalescent plasma when stored at 4° Celsius for at least 6 weeks. Transfusion 2020 Oct;60(10):2457-2459 [FREE Full text] [CrossRef] [Medline]
  292. Jahrsdörfer B, Kroschel J, Ludwig C, Corman V, Schwarz T, Körper S, et al. Independent side-by-side validation and comparison of 4 serological platforms for SARS-CoV-2 antibody testing. J Infect Dis 2021 Mar 03;223(5):796-801 [FREE Full text] [CrossRef] [Medline]
  293. Johnson M, Wagstaffe H, Gilmour K, Mai A, Lewis J, Hunt A, et al. Evaluation of a novel multiplexed assay for determining IgG levels and functional activity to SARS-CoV-2. J Clin Virol 2020 Sep;130:104572 [FREE Full text] [CrossRef] [Medline]
  294. di Mauro G, Scavone C, Rafaniello C, Rossi F, Capuano A. SARS-Cov-2 infection: response of human immune system and possible implications for the rapid test and treatment. Int Immunopharmacol 2020 Jul;84:106519 [FREE Full text] [CrossRef] [Medline]
  295. Recommendations for investigational COVID-19 convalescent plasma. US Food and Drug Administration.   URL: https:/​/www.​​vaccines-blood-biologics/​investigational-new-drug-ind-or-device-exemption-ide-process-cber/​recommendations-investigational-covid-19-convalescent-plasma [accessed 2020-06-01]
  296. FDA in brief: FDA updates emergency use authorization for COVID-19 convalescent plasma to reflect new data. US Food and Drug Administration.   URL: http:/​/www.​​news-events/​fda-brief/​fda-brief-fda-updates-emergency-use-authorization-covid-19-convalescent-plasma-reflect-new-data [accessed 2021-02-16]
  297. Klein S, Pekosz A, Park H, Ursin R, Shapiro J, Benner S, et al. Sex, age, and hospitalization drive antibody responses in a COVID-19 convalescent plasma donor population. J Clin Invest 2020 Nov 02;130(11):6141-6150. [CrossRef] [Medline]
  298. Asrani P, Hassan MI. SARS-CoV-2 mediated lung inflammatory responses in host: targeting the cytokine storm for therapeutic interventions. Mol Cell Biochem 2021 Feb;476(2):675-687 [FREE Full text] [CrossRef] [Medline]
  299. Kato H, Uruma M, Okuyama Y, Fujita H, Handa M, Tomiyama Y, et al. Incidence of transfusion-related adverse reactions per patient reflects the potential risk of transfusion therapy in Japan. Am J Clin Pathol 2013 Aug;140(2):219-224. [CrossRef] [Medline]
  300. Chang L, Yan Y, Wang L. Coronavirus disease 2019: coronaviruses and blood safety. Transfus Med Rev 2020 Apr;34(2):75-80 [FREE Full text] [CrossRef] [Medline]
  301. Keil SD, Ragan I, Yonemura S, Hartson L, Dart NK, Bowen R. Inactivation of severe acute respiratory syndrome coronavirus 2 in plasma and platelet products using a riboflavin and ultraviolet light-based photochemical treatment. Vox Sang 2020 Aug;115(6):495-501 [FREE Full text] [CrossRef] [Medline]
  302. Abraham J. Passive antibody therapy in COVID-19. Nat Rev Immunol 2020 Jul;20(7):401-403 [FREE Full text] [CrossRef] [Medline]
  303. Halstead SB, Akkina R. COVID-19 and SARS Coronavirus 2: antibodies for the immediate rescue and recovery phase. Front Immunol 2020;11:1196. [CrossRef] [Medline]
  304. Luchsinger LL, Ransegnola BP, Jin DK, Muecksch F, Weisblum Y, Bao W, et al. Serological assays estimate highly variable SARS-CoV-2 neutralizing antibody activity in recovered COVID-19 patients. J Clin Microbiol 2020 Nov 18;58(12):e02005-e02020 [FREE Full text] [CrossRef] [Medline]
  305. Ibarrondo FJ, Fulcher JA, Goodman-Meza D, Elliott J, Hofmann C, Hausner MA, et al. Rapid decay of anti-SARS-CoV-2 antibodies in persons with mild Covid-19. N Engl J Med 2020 Sep 10;383(11):1085-1087 [FREE Full text] [CrossRef] [Medline]
  306. Gudbjartsson DF, Norddahl GL, Melsted P, Gunnarsdottir K, Holm H, Eythorsson E, et al. Humoral immune response to SARS-CoV-2 in Iceland. N Engl J Med 2020 Oct 29;383(18):1724-1734 [FREE Full text] [CrossRef] [Medline]
  307. Salazar G, Zhang N, Fu T, An Z. Antibody therapies for the prevention and treatment of viral infections. NPJ Vaccines 2017;2:19. [CrossRef] [Medline]
  308. Chatterjee SK, Saha S, Munoz MNM. Molecular pathogenesis, immunopathogenesis and novel therapeutic strategy against COVID-19. Front Mol Biosci 2020;7:196. [CrossRef] [Medline]
  309. Ou X, Liu Y, Lei X, Li P, Mi D, Ren L, et al. Characterization of spike glycoprotein of SARS-CoV-2 on virus entry and its immune cross-reactivity with SARS-CoV. Nat Commun 2020 Mar 27;11(1):1620. [CrossRef] [Medline]
  310. Peng Y, Mentzer AJ, Liu G, Yao X, Yin Z, Dong D, Oxford Immunology Network Covid-19 Response T cell Consortium, ISARIC4C Investigators, et al. Broad and strong memory CD4 and CD8 T cells induced by SARS-CoV-2 in UK convalescent individuals following COVID-19. Nat Immunol 2020 Nov;21(11):1336-1345. [CrossRef] [Medline]
  311. Toor SM, Saleh R, Sasidharan Nair V, Taha RZ, Elkord E. T-cell responses and therapies against SARS-CoV-2 infection. Immunology 2021 Jan;162(1):30-43 [FREE Full text] [CrossRef] [Medline]
  312. Li R, Ma X, Deng J, Chen Q, Liu W, Peng Z, et al. Differential efficiencies to neutralize the novel mutants B.1.1.7 and 501Y.V2 by collected sera from convalescent COVID-19 patients and RBD nanoparticle-vaccinated rhesus macaques. Cell Mol Immunol 2021 Feb 12:1 [FREE Full text] [CrossRef] [Medline]
  313. Diamond M, Chen R, Xie X, Case J, Zhang X, VanBlargan L, et al. SARS-CoV-2 variants show resistance to neutralization by many monoclonal and serum-derived polyclonal antibodies. Res Square. Preprint posted online on February 10, 2021. [CrossRef] [Medline]
  314. Seehra J, Pandis N, Koletsi D, Fleming P. Use of quality assessment tools in systematic reviews was varied and inconsistent. J Clin Epidemiol 2016 Jan;69:179-84.e5. [CrossRef] [Medline]
  315. Armijo-Olivo S, Stiles CR, Hagen NA, Biondo PD, Cummings GG. Assessment of study quality for systematic reviews: a comparison of the Cochrane Collaboration Risk of Bias Tool and the Effective Public Health Practice Project Quality Assessment Tool: methodological research. J Eval Clin Pract 2012 Feb;18(1):12-18. [CrossRef] [Medline]
  316. Raynaud M, Zhang H, Louis K, Goutaudier V, Wang J, Dubourg Q, et al. COVID-19-related medical research: a meta-research and critical appraisal. BMC Med Res Methodol 2021 Jan 04;21(1):1 [FREE Full text] [CrossRef] [Medline]
  317. Keith P, Day M, Choe C, Perkins L, Moyer L, Hays E, et al. The successful use of therapeutic plasma exchange for severe COVID-19 acute respiratory distress syndrome with multiple organ failure. SAGE Open Med Case Rep 2020;8:2050313X20933473 [FREE Full text] [CrossRef] [Medline]
  318. Shander A, Goobie S, Warner M, Aapro M, Bisbe E, Perez-Calatayud A, International Foundation of Patient Blood Management (IFPBM) and Society for the Advancement of Blood Management (SABM) Work Group. Essential role of patient blood management in a pandemic: a call for action. Anesth Analg 2020 Jul;131(1):74-85 [FREE Full text] [CrossRef] [Medline]

ACE-2: angiotensin-converting enzyme 2
CP: convalescent plasma
ELISA: enzyme-linked immunosorbent assay
EPHPP: Effective Public Health Practice Project
EUA: Emergency Use Authorization
FDA: Food and Drug Administration
Ig: immunoglobulin
MERS-CoV: Middle East respiratory syndrome–related coronavirus
OR: odds ratio
PCR: polymerase chain reaction
PRISMA: Preferred Reporting Items for Systematic Reviews and Meta-Analyses
RBD: receptor binding domain
RCT: randomized controlled trial
ROM: ratio of mean
SARS-CoV: severe acute respiratory syndrome–related coronavirus
TACO: transfusion-associated circulatory overload
TRALI: transfusion-related lung injury

Edited by T Sanchez; submitted 10.11.20; peer-reviewed by V Curin, N Hardikar; comments to author 27.01.21; accepted 19.02.21; published 07.04.21


©Henry T Peng, Shawn G Rhind, Andrew Beckett. Originally published in JMIR Public Health and Surveillance (, 07.04.2021.

This is an open-access article distributed under the terms of the Creative Commons Attribution License (, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work, first published in JMIR Public Health and Surveillance, is properly cited. The complete bibliographic information, a link to the original publication on, as well as this copyright and license information must be included.